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Human blood-brain barrier endothelial cells derived from 
pluripotent stem cells 
Eric V. Shusta, Ethan S. Lippmann, Samira M. Azarin, Sean P. 
Palecek. 
Presenter affiliation: University of Wisconsin, Madison, Wisconsin. 
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4 
  
Predicting small molecule permeation across the blood-brain 
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barrier development in Drosophila 
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28 
  
microRNAs control brain endothelial cell barrier function 
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 1 
HUMAN BLOOD-BRAIN BARRIER ENDOTHELIAL CELLS 
DERIVED FROM PLURIPOTENT STEM CELLS 
 
Eric V Shusta, Ethan S Lippmann, Samira M Azarin, Sean P Palecek  
 
University of Wisconsin, Chem and Biol Engineering, Madison, WI, 53706 
 
The blood-brain barrier (BBB) plays an important role in brain health and 
disease by selectively trafficking compounds to and from the brain across 
its endothelial interface. For decades, researchers have cultured brain 
microvascular endothelial cells (BMECs) ex vivo to serve two main 
purposes: to elucidate the molecular mechanisms responsible for BBB 
differentiation and regulation, and to establish a platform for high 
throughput screening of brain-penetrating pharmaceuticals. Unfortunately, 
while much success has been achieved in the isolation and in vitro culture 
of animal BMECs, progress in the establishment of a robust human in vitro 
BBB model has been more limited. Human BMEC platforms either possess 
poor barrier properties that do not appropriately represent the BBB or are 
derived from sources with insufficient yield to allow widespread use of the 
model. As such, we have devised a novel method for high-yield 
differentiation of human pluripotent stem cells to endothelial cells with 
specific properties of the BBB, including selective responsiveness to 
astrocyte co-culture, high trans-endothelial electrical resistance, low passive 
permeability, and polarized transport protein activity. Importantly, we 
provide evidence that the BBB specification process occurs in concert with 
Wnt/β-catenin signaling, which is the pathway identified for BBB 
differentiation in transgenic rodent studies. Thus, this system has the 
potential to provide a robust human BMEC platform for high throughput 
screening of neuropharmaceuticals and will be useful for studies of BBB 
development and maturation that were previously intractable in humans. 
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DEVELOPMENT OF GENETIC METHODS TO IMAGE DYNAMIC 
STRUCTURAL AND FUNCTIONAL CHANGES IN THE 
MAMMALIAN BLOOD BRAIN BARRIER IN HEALTH AND DISEASE 
 
Dritan Agalliu*1, Axel Nimmerjahn*2, Ahmet Arac3, Mark Schintzer2, Ben 
A Barres1  
 
1Stanford University, Neurobiology, Stanford, CA, 94305, 2Stanford 
University, Biological Sciences & Applied Physics, Stanford, CA, 94305, 
3Stanford University, Neurosurgery, Stanford, CA, 94305 
 
The endothelial cells in the Central Nervous System (CNS) form a barrier to 
blood-borne molecules that is essential for CNS function by three 
mechanisms: a) tight junctions (TJs); b) few caveolae with a low rate of 
transcytosis; and c) transporter systems. Abnormalities in blood brain 
barrier (BBB) permeability are found in many CNS diseases such as stroke 
or multiple sclerosis. However, it is unclear which structural components of 
the BBB are predominantly affected in these CNS diseases. The timing and 
extent of BBB structural changes during disease progression are also 
unknown. 
To address these questions, we have generated two novel lines of transgenic 
mice that label two components necessary for BBB integrity namely, TJs 
and caveolae. These lines express in all endothelial cells either a fusion 
protein of eGFP with the TJ protein Claudin-5 or the red fluorescent protein 
pmKate2 with the caveolar transmembrane protein Caveolin-1. We have 
imaged TJs in the CNS endothelium of eGFP::Claudin-5 transgenic mice 
using a two-photon laser microscope, and combined this with fluorescent 
molecular tracers to correlate structural changes in TJ protein localization 
with diffusion of tracers across the BBB in healthy mice and those suffering 
from stroke. We have found that TJs are very stable structures in the CNS 
endothelium of healthy transgenic mice and the tracers are retained within 
the CNS capillaries. Surprisingly, although BBB functional integrity is 
impaired in transgenic mice that have undergone middle cerebral artery 
occlusion - a mouse model for stroke - as early as 12-14 hours after the 
disease, TJs seem very stable at least within 24-30 hours post-lesion at the 
ischemic core region by light microscopy. However, TJs were abnormal 
between 48-56 hours post stroke at the ischemic core region. We also plan 
to image pmKate2::Caveolin-1 transgenic mice to analyze changes in 
transcytosis rates across CNS capillaries in healthy and disease states. This 
will allow us to elucidate the mechanisms that impair BBB integrity during 
various CNS diseases and develop therapies to restore it. 
*equal contribution 
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WNT SIGNALING IN THE DEVELOPMENT OF BBB MODELS IN 
VITRO 
 
Roberta Paolinelli1, Monica Corada1, Noemi Rudini1, Luigi Maddaluno1, 
Maria Grazia Lampugnani1,3, Elisabetta Dejana1,2  
 
1IFOM, Vascular Biology Lab, Milan, 20139, Italy, 2University of Milan, 
Biomolecular Sciences , Milan, 20126, Italy, 3Mario Negri Institute, 
Pharmacological Research, Milan, 20156, Italy 
 
The blood brain barrier (BBB) maintains the homeostasis of the brain 
microenvironment, which is crucial for neuronal activity and function. The 
main cellular basis of its restrictive nature are the brain microvascular 
endothelial cells (BMECs), responsible for the transport of metabolites, 
precursors and nutrients from the blood to the brain, along with the 
association of other cell types of the neurovascular unit. BMECs are 
characterized by the absence of fenestrations, a low level of pinocytic 
vesicles and an elaborate junctional complex formed by both tight junctions 
(TJs) and adherens junctions (AJs). The Wnt canonical signaling pathway 
regulates fundamental aspects of development including cell fate 
specification, proliferation, survival and overall organogenesis. Endothelial 
Wnt/β-catenin signaling is one of the major pathway that regulates 
induction and maintenance of BBB characteristics during embryonic and 
postnatal development. Stabilization of β-catenin in vivo enhances BBB 
maturation by inducing expression of TJ protein Claudin3 (Cldn3), which is 
predominantly present in brain ECs, and down-regulation of the 
plasmalemma vesicle-associated protein (Plvap), which is usually only 
expressed on immature brain endothelium. Most in vitro BBB models 
proposed so far are based on primary co-cultures of brain ECs and 
astrocytes or glial cells. An easier and reliable in vitro model of BBB is still 
missing, limiting the possibility to perform drugs screenings able to cross or 
modify the barrier. An important advancement in the development of an 
alternative optimal and reproducible screening assay is the use of 
immortalized endothelial cell lines. We focused on a widely usable-in-the-
field BBB in vitro system with no need of co-culture, by culturing freshly 
isolated brain endothelium (primary mouse endothelial cells-MBECs), or 
bEnd5, a polyoma middle T-oncogen-immortalized mouse brain 
endothelioma), in contact with Wnt3a, which acts through β-catenin, or with 
chemicals known to stabilize β-catenin such as inhibitors of glycogen 
synthase kinase-3β (GSK3β). Interestingly, these treatments resulted in the 
activation of β catenin signaling (Axin2 upregulation) and induction of 
barrier characteristics (Cldn3 upregulation and Plvap downregulation). 
Importantly, as readout of BBB properties, we have defined an identikit of 
the most important genes known to be expressed in BMECs. Our models 
will be instrumental not only for further studies on the molecular 
mechanisms which induce BBB properties, but also for the screening of 
agents and drugs to modify BBB permeability. 
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TARGETED BLOOD-BRAIN BARRIER DISRUPTION IN 
NONHUMAN PRIMATES USING FOCUSED ULTRASOUND AND 
MICROBUBBLES 
 
Nathan McDannold1, Costas D Arvanitis1, Natalia Vykhodtseva1, Margaret S 
Livingstone2  
 
1Brigham & Women's Hospital, Harvard Medical School, Radiology, Boston, 
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Small animal experiments have shown that ultrasound bursts combined with a 
microbubble agent can locally and temporarily disrupt the blood-brain barrier 
(BBB), providing a potential noninvasive means for targeted drug delivery in 
the CNS. This work was a safety study of targeted BBB disruption (BBBD) 
with a clinical MR-guided focused ultrasound (MRgFUS) system in nonhuman 
primates.  
 
Methods: Our Institutional Animal Care and Use Committee approved the 
experiments. Sonication was performed transcranially in 4 anesthetized adult 
male rhesus macaques with a clinical MRgFUS system (ExAblate 4000 brain, 
InSightec), which uses a 1024-channel phased array (30 cm hemisphere; 220 
kHz) integrated with a 3T MRI. Multiple locations in each brain were targeted 
via electronic beam steering with 70s sonications (10 ms bursts; 1 Hz PRF). In 
one animal, the beam was steered dynamically during sonication to disrupt a ~1 
cm³ volume with a single exposure. At the start of each sonication, ultrasound 
contrast agent (Definity, 10 µl/kg) was injected intravenously. BBBD was 
evaluated in contrast-enhanced T1-weighted (Magnevist, 0.2 ml/kg). The 
presence of edema and erythrocyte extravasation was evaluated in T2 and T2*-
weighted imaging, respectively. Targets included the thalamus, putamen, 
cerebellum, cortex, and white matter. In this preliminary parametric study, 
acoustic power ranged from 0.5-10 W. 
 
Results and Conclusions: BBBD was observed at 27/38 targeted locations. 
Eleven sonications at 0.5-1W in one animal did not produce BBBD; sonication 
a week later at different targets at 1.5-2W resulted in BBBD. Changes in 
T2/T2*-weighted imaging, suggesting tissue damage, were evident for 
sonication at 4W and above (N=6), and for two locations (1.5, 2W) in the 
thalamus. BBBD without MRI-evident damage was achieved in 19 locations (1-
3W). In one location targeted at 10W, secondary damage was evident between 
the target and the transducer. Otherwise, the sonication effects appeared to be 
fully contained to the target location and did not appear to affect any other brain 
region. Targeting multiple overlapping locations via dynamic steering produced 
contiguous volumes of BBBD. 
 
Overall, these data demonstrate that it is possible to use a clinical MRgFUS 
system for targeted BBBD in multiple brain structures in a large animal model 
without producing other MRI-evident effects on surrounding tissues. Future 
work will evaluate histological and functional effects produced by these 
exposures and investigate methods to guide the procedure. 
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PREDICTING SMALL MOLECULE PERMEATION ACROSS THE 
BLOOD-BRAIN BARRIER 
 
Matthew P Jacobson  
 
UCSF, Pharmaceutical Chemistry, San Francisco, CA, 94158 
 
I will describe my group's efforts to model key processes underlying the 
partitioning of drugs across the blood-brain barrier. The first key process is 
passive permeation across membranes, and I will discuss the key physical 
aspects of this process and how they can be computed, and a hypothesis that 
the lipid composition in the blood-brain barrier may account for differences 
in passive membrane permeability relative to, e.g., intestinal membrane 
permeation. The second key process is active efflux by P-glycoprotein. We 
are exploiting the recently published structures of P-gp to better understand 
the physico-chemical determinants of this process and reconcile previously 
confusing structure-activity relationships. Finally I will discuss preliminary 
efforts to address other aspects of partitioning across the BBB, including 
serum protein binding and interactions with other transporters. 
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INVERSE RELATIONSHIP BETWEEN AFFINITY AND BRAIN 
UPTAKE OF RECEPTOR-MEDIATED TRANSCYTOSIS TARGETING 
ANTIBODIES 
 
Joy Yu, Yin Zhang, Jasvinder Atwal, Yan Wu, Kwame Hoyte, Yanmei Lu, 
Margaret Kenrick, Saileta Prabhu, Ryan J Watts, Mark Dennis  
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Monoclonal antibodies have vast therapeutic potential for treatment of 
central nervous system (CNS) diseases, but their passage into the brain is 
restricted by the blood-brain barrier (BBB). Here we explore receptor-
mediated transcytosis (RMT) pathways of brain endothelial cells as a 
potential mechanism to deliver antibodies across the BBB. We demonstrate 
that trace levels of anti-transferrin receptor (TfR) antibodies accumulate in 
the brain after a single systemic dose in mice; however, distribution of anti-
TfR appears to remain localized to brain vasculature. At therapeutically 
relevant dose levels, however, we observe that antibody distribution after 
systemic administration changes from vascular to neuronal 24 hours after 
administration, suggesting that a significant amount of antibody had 
transcytosed through brain endothelial cells to reach the parenchyma. 
Additionally, we discovered that the magnitude of antibody uptake was 
inversely related to its binding affinity to TfR. This novel insight into the 
inverse relationship between affinity and brain uptake suggests that the 
ability of bound antibody to dissociate from the receptor is integral to its 
successful transcytosis through the vasculature. Proof of this BBB transport 
was achieved using a bispecific antibody that binds both TfR and the 
amyloid precursor protein (APP) cleavage enzyme, β-secretase (BACE1). 
Systemic administration of anti-TfR/BACE1 produced a greater than 5-fold 
increased accumulation in the brain, compared to monospecific anti-
BACE1. Localization of anti-TfR/BACE1 was found to be distinctly 
neuronal 24 hours after injection. Given that inhibition of neuronal BACE1 
activity has been shown to reduce amyloid beta production, this bispecific 
anti-TfR/BACE1 antibody introduces a promising and novel therapeutic 
candidate for the treatment of Alzheimer’s disease. Furthermore, this RMT-
based bispecific targeting technology opens the door for a wide range of 
potential therapeutics for CNS diseases. 
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IMAGING BORRELIA IN A MURINE MODEL 
 
Alexandru Movila1, Star M Dunham-Ems2, Melissa J Caimano2, Nico van 
Rooijen3, Justin D Radolf2, Ute Frevert1  
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Intravital microscopy has had a major impact on our understanding of the 
behavior of a broad range of microorganisms within the intact host. By 
confirming some hypotheses, refuting others, and revealing unexpected new 
mechanisms, in vivo imaging has provided an entirely new insight into the 
dynamics of infectious disease pathogenesis. The mouse has been 
extensively used to study Borrelia burgdorferi induced heart and joint 
disease, but there is currently no reliable small animal model for 
neuroborreliosis. Under normal circumstances, spirochetes entering the 
bloodstream are rapidly eliminated by Kupffer cells, the resident 
macrophages of the liver. To extend Borrelia circulation within the 
cardiovascular system, thus enhancing exposure of the cerebral 
microvasculature to the spirochetes, we depleted mice of all hepatic and 
splenic macrophages with liposome-encapsulated clodronate prior to 
infection. Analysis of the integrity of the blood brain barrier revealed 
transient Evans blue leakage in clodronate liposome-treated infected mice; 
neither control liposome-treated infected mice nor clodronate liposome-
treated uninfected mice exhibited vascular impairment. The effect of B. 
burgdorferi on the cortical microvasculature was studied by dynamic 
imaging of mice inoculated with fluorescent spirochetes and markers for 
inflammation and coagulation. 
 
The work was supported by a grant from the Neurology Research 
Foundation 
 8 
ESTABLISHMENT OF A NEUROEPITHELIAL BARRIER BY 
CLAUDIN-5A IS ESSENTIAL FOR ZEBRAFISH BRAIN 
VENTRICULAR LUMEN EXPANSION 
 
Ingolf E Blasig1, Jingjing Zhang,2 Jörg Piontek,1 Hartwig Wolburg,3 
Christian Piehl,1 Martin Liss,1,2 Cécile Otten,2 Annabel Christ,2 Thomas E. 
Willnow,2 Salim Abdelilah-Seyfried,2  
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Lumen expansion driven by hydrostatic pressure occurs during many 
morphogenetic processes. It is well established that members of the claudin 
family of transmembrane tight junction proteins determine paracellular 
tightness of epithelial and endothelial tissue barriers. However, functional 
evidence for a role of claudins in the morphogenesis of lumenized organs 
has been scarce. Here, we identify claudin-5a as a core component of an 
early cerebral-ventricular barrier system that is required for ventricular 
lumen expansion in the zebrafish embryonic brain before the establishment 
of the embryonic blood–brain barrier. Loss of claudin-5a or expression of a 
tight junction-opening claudin-5a mutant reduces brain ventricular volume 
expansion without disrupting the polarized organization of the 
neuroepithelium. Perfusion experiments with the electron-dense small 
molecule lanthanum nitrate reveal that paracellular tightness of the cerebral-
ventricular barrier decreases upon loss of claudin-5a. Genetic analyses show 
that the apical neuroepithelial localization of claudin-5a depends on 
epithelial cell polarity and provide evidence for concerted activities between 
claudin-5a and Na,K-ATPase during luminal expansion of brain ventricles. 
These data establish an essential role of a barrier-forming claudin in 
ventricular lumen expansion, thereby contributing to brain morphogenesis. 
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A GENETIC APPROACH FOR THE ORGANIZATION AND 
FUNCTION OF THE BLOOD-BRAIN BARRIER IN DROSOPHILA 
 
Hiroshi Kanda, Rieko Shimamura, Hideyuki Okano  
 
Keio University School of Medicine, Department of Physiology., Tokyo, 
160-8582, Japan 
 
In Drosophila, Blood-Brain Barrier (BBB) is provided by a type of glia, 
subperineurial glia (SPG), that form paracellular barrier through Septate 
Junctions (SJs) that have functional and molecular similarities to vertebrate 
Tight Junctions (TJs). It has also been revealed that Drosophila SPG also 
has the xenobiotic exclusion system which is achieved by conserved fly 
ATP-binding cassette (ABC) transporter(s). We thus aimed to use 
Drosophila as a model organism to study the conserved molecular 
mechanisms for regulating the BBB functions in vivo using its powerful 
genetics.  
In order to address this issue, we have set up a genetic system with a 
combination of dye-injection assay to perform a large-scale screen for 
identifying novel genes that are involved in the regulation of the integrity of 
paracellular barrier function. In this system, double-stranded RNAs of 
single genes are overexpressed under the control of SPG-specific driver to 
induce the ‘BBB-specific RNAi’ in vivo. In our system, the knockdown of a 
G-protein coupled receptor, Moody, which is previously reported to be 
required for the integrity of SJs, or Kune-kune, a Drosophila Claudin family 
protein, resulted in the diffusion of dye into central nervous system. Among 
candidates identified in the screen, we have picked up several genes and 
reconfirmed that the mutant animals for these genes also showed the dye-
penetration phenotype when they were examined the BBB function. We are 
currently further performing the screen, as well as studying the molecular 
functions of genes identified in it. 
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DEVELOPING TRANSGENIC ZEBRAFISH FOR HIGH-
THROUGHPUT GENETIC AND SMALL MOLECULE SCREENING OF 
THE BLOOD-BRAIN AND BLOOD-CSF BARRIERS 
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The field of brain barrier biology could greatly benefit from the creation of 
animal models suitable for high-throughput genetic and small-molecule 
screens. To address this problem, we are exploiting the strengths of 
zebrafish as a model organism. Zebrafish provide many advantages for the 
study of complex biological systems like the BBB and BCB. They are 
vertebrates; transparent; small; develop rapidly outside of the mother; and 
are amenable to high-throughput screening strategies. Our preliminary 
studies and recent work of others demonstrate that zebrafish possess the 
structural and functional properties of the brain barriers, further indicating 
the utility of this animal model. For this study, we are creating two 
transgenic zebrafish lines that “report” upon the developmental and 
functional status of the brain barriers in vivo. These transgenic lines will 
allow for rapid, in vivo examination of brain barrier integrity without 
having to inject, dissect, or sacrifice the animal. Thus, instead of analyzing 
a few animals at a time using antiquated techniques, we will be able to 
examine thousands of animals daily, significantly increasing the rate of 
discovery. Furthermore, we have generated an additional transgenic line 
that expresses GFP within the choroid plexus of the BCB. Our long-term 
goals are to use these transgenic zebrafish to screen for genes and small 
molecules that modulate brain barriers, ultimately leading to the discovery 
of drugs that allow controlled access of therapeutic agents into the brain. 
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THE CAMP EFFECTOR PKA MEDIATES GPCR SIGNALING IN 
BLOOD-BRAIN BARRIER DEVELOPMENT IN DROSOPHILA 
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The blood-brain barrier (BBB) of Drosophila is established by a thin layer 
of surface glia, which ensheath the nervous system and insulate it against 
the potassium-rich hemolymph by forming intercellular septate junctions 
(SJs). We have previously identified Moody, a novel G protein-coupled 
receptor (GPCR), is required in the development and maintenance of the 
BBB. However, the precise mechanism underlying GPCR signaling during 
BBB development has remained obscure. Here we show that cAMP-
dependent protein kinase A (PKA), a major effector of cAMP, is required 
for the insulation of the nervous system and plays a critical role in the 
Moody signaling pathway. At the cellular level, PKA not only regulates cell 
shape by reorganization of the actin and microtubule cytoskeleton, but also 
affects the expression and proper localization of SJ components to the 
interface with neighboring surface glia, which are required for effective 
insulation. Strikingly, the PKA catalytic subunit DC0 shows highly 
polarized localization in the surface glia, and both over- and underactivity 
of PKA result in severe insulation defects but totally opposite cell biological 
phenotype, indicating that the cAMP/PKA pathway acts downstream of 
Moody and produces a local signal within the cell. Our study demonstrates 
a novel role of cAMP/PKA signaling in the regulation of the intercellular 
SJs organization that generates BBB integrity, and provides new insights 
into the molecular and cellular mechanism of Moody-regulated BBB 
development and maintenance. 
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INHIBITORS FOR NEUROAIDS 
 
Harris A Gelbard1, Stephen Dewhurst2, Sanjay Maggirwar2, Val 
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Combination antiretroviral therapy has dramatically changed the phenotype 
of HIV-associated neurocognitive disease (HAND), but has neither 
eradicated it or decreased its prevalence. Thus we hypothesize there is a 
reversible metabolic component of HAND with the molecular etiologic 
target of mixed lineage kinase type 3 (MLK3) that we can define in 
laboratory models, design rational adjunctive neuroprotective drugs for 
using a series of lead compounds (URMC-099c*), then test in our in vitro 
and in vivo models of NeuroAIDS, with the goal of advancing the most 
efficacious development compound to the FDA for IND filing. In previous 
studies, we have validated MLK3 as an enzyme pathologically activated by 
HIV-1 neurotoxins, then successfully developed a small molecule MLK3 
inhibitor, URMC-099, capable of achieving therapeutic concentrations in 
the CNS. Using our industry partner to synthesize a series of small molecule 
MLK3 inhibitors with drug-like properties and a favorable profile for 
blood-brain barrier penetration, we have used URMC-099 and -099c* in our 
models of HAND to investigate their ability to reverse neuroinflammation 
and synaptodendritic damage. Thus, we initially investigate URMC-099c* 
in in vivo models of HAND, using irradiation chimera of mice transgenic 
for XFP to identify both peripheral and central mononuclear phagocytes and 
neurons, while cerebral microvessels are identified by infusion of 
fluorophores. After defining pathologic phenotypes for peripheral and 
central immune effector cells inside and outside cerebral microvessels, as 
well as neuronal synapses, we quantitate the ability of URMC-099c* to 
ameliorate these phenotypes, accompanied by ex vivo or in vitro dissection 
of relevant signaling pathways upstream and downstream of MLK3. 
Ultimately, the most promising lead compound is further evaluated for 
neuroprotective efficacy in a humanized CD34+ murine model of HAND 
and finally in a rhesus macaque model of SIV. In aggregate, this defines a 
testing funnel for further structure activity relationship (SAR) work relevant 
to advancement of URMC-099c* to development compound status, with the 
goal of applying to the NIH Rapid Access for Interventional Development 
(RAID) program for good laboratory practice (GLP) scale-up and 
manufacture, as well as remaining safety and toxicity studies of our 
development compound, prior to filing an IND with the FDA. 
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GROUP B STREPTOCOCCUS EXPLOITS INTEGRIN MACHINERY 
FOR ACTIVATION OF NEUTROPHIL SIGNALING PATHWAYS AND 
EFFICIENT BLOOD-BRAIN BARRIER PENETRATION 
 
Anirban Banerjee, Ellese Carmona, Michael A Gurney, Christopher Carlos, 
Kelly S Doran  
 
San Diego State University, Biology, San Diego, CA, 92115 
 
Group B Streptococcus (GBS) is the leading cause of meningitis in newborn 
infants and also increasingly associated with infections in adults. We have 
demonstrated previously that GBS clinical isolate NCTC10/84 express pili 
and that PilA, which is thought to be located at the tip of the pilus, 
contributes to GBS adherence to brain endothelium. In this study, we sought 
to examine the global transcriptional response of the human brain 
microvascular endothelial cells (hBMEC), the single cell layer which 
comprises the blood-brain barrier (BBB), to GBS PilA. Using microarray 
analysis we found that GBS infection of hBMEC resulted in a significant 
induction of genes acting to orchestrate neutrophil chemotaxis including IL-
8, CCL-20, IL-6, CXCL-1 and CXCL-2. In contrast infection with an 
isogenic GBS PilA-deficient mutant resulted in a marked reduction in 
expression of these genes. These results were confirmed using real time RT-
PCR and protein based assays. Recombinant PilA proteins purified from 
various GBS serotypes also elicited chemokine expression. Additionally, 
neutrophil chemotaxis to the site of infection in vivo was found to be 
dependent on PilA; decreased neutrophil recruitment and tissue damage in 
the brain were also observed in a murine model of hematogenous meningitis 
following infection with the PilA-deficient GBS strain. We further 
demonstrated that PilA binds to collagen, which acts as a molecular bridge, 
promoting GBS interaction with the α2β1 integrin expressed in BBB 
endothelium. This interaction involves focal adhesion kinase which results 
in both bacterial internalization and proinflammatory cytokine release. Our 
studies suggest that GBS PilA hijacks integrin machinery to promote 
efficient penetration of BBB endothelium and characteristic neutrophilic 
inflammation during acute bacterial meningitis. 
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ECRG4 GENE IN THE CENTRAL NERVOUS SYSTEM: A ROLE FOR 
AUGURIN IN NEUROPROGENITOR CELL GROWTH AND CSF 
HYDRODYNAMICS 
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The choroid plexus (CP) is largely responsible for the content and 
composition of cerebrospinal fluid (CSF) either through the translocation of 
hormones from blood, or via their de novo synthesis in, and secretion by, 
choroid epithelia. Because these CSF hormones can potentially affect cell 
function throughout the central nervous system (CNS), it is critical to 
determine their role in normal CNS homeostasis. One newly recognized 
factor is augurin, a 14,000 Dalton secreted protein that is encoded by a 
candidate, and epigenetically regulated, tumor suppressor gene called 
esophageal cancer related gene-4 (ecrg4). Ecrg4 gene expression in the CP 
was studied by in situ hybridization and quantitative RT-PCR. Augurin was 
detected by immunoblotting, immunohistochemistry and ELISA. The 
biological consequence of transient augurin over- and under-production in 
the CNS was studied by transduction of CP epithelium and ependyma after 
intracerebroventricular injection of an adenovirus containing the ecrg4 gene 
and by gene knockdown in the developing Zebrafish, respectively. Gene 
expression analyses reveal that, in the CNS, ecrg4 mRNA predominantly 
localizes to choroid plexus epithelial (CPe), ventricular ependymal and 
aqueductal canal cells. This distribution was confirmed by 
immunohistochemical analyses quantitative PCR. Immunoblotting and 
ELISA show that transduced CPe cells synthesize and secrete augurin. Over 
expression of ecrg4 in vivo decreased subependymal progenitor cell 
proliferation that is observed after injury and its knock down in developing 
zebrafish embryos caused increased cell proliferation and dose-dependent 
ventriculomegaly that was reversible by co-injection of ECRG4 mRNA. 
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TRANSCRIPTIONAL PROFILING OF THE BLOOD-BRAIN BARRIER 
 
Richard Daneman, Lu Zhou, Dritan Agalliu, John D Cahoy, Amit Kaushal, 
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The blood-brain barrier (BBB) maintains brain homeostasis and limits the 
entry of toxins and pathogens into the brain. Despite its importance, little is 
known about the molecular mechanisms regulating its development and 
function. In this study we have developed novel methods to separate the 
cellular components of the BBB, brain endothelial cells and pericytes, 
allowing me to highly purify and gene profile these cells. By comparing the 
transcriptional profile of brain endothelial cells with those purified from the 
liver and lung, we have generated a comprehensive resource of transcripts 
that are specific to the BBB. Through this comparison we have identified 
novel tight junction molecules, transporters, metabolic enzymes, signaling 
components, and unknown transcripts that are expressed specifically by 
CNS endothelial cells. Wnt and RXRα signaling cascades are specifically 
enriched at the BBB, implicating these pathways in regulating this vital 
barrier. These endothelial and pericyte transcriptomes provide a useful 
resource for the neuroscience community to better understand brain 
angiogenesis and the blood-brain barrier.  
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PERICYTES REGULATE BLOOD-BRAIN BARRIER FORMATION 
DURING EMBRYOGENESIS 
 
R Daneman, L Zhou, A A Kebede, B A Barres  
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Although the properties of the BBB are manifested within endothelial cells, 
transplantation studies have demonstrated that these properties are induced 
by signals from the microenvironment of the CNS. Due to the close spatial 
relationship between astrocytes and endothelial cells, astrocytes have been 
thought to induce the BBB during postnatal development, however the 
timing of BBB formation remains controversial. Here we demonstrate that 
the BBB is formed antigenically and functionally during early 
embryogenesis, days before glia are generated. This demonstrates that 
astrocytes are not involved in BBB induction. We further explore the role of 
CNS pericytes in regulating the barrier, examining BBB function, structure 
and gene expression in pericyte-deficient mice, as well as the ability of 
pericytes to induce barrier properties in endothelial cells in co-culture 
experiments. We find that pericytes are required for BBB formation during 
development, and that these cells regulate functional aspects of the BBB, 
including tight junction structure, rates of transcytosis, and limiting CNS 
immune infiltration. We further show that pericytes accomplish this not by 
inducing BBB-specific gene expression, but by inhibiting the expression of 
genes which increase the permeability of the CNS vessels. 
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Drosophila male courtship consists of a sequence of stereotyped steps of 
behavior that can be studied and quantified in the lab. It has been known for 
some time that specific regions in the brain of a male are important for 
successful courtship and that the cells in these regions are characterized by 
the presence of two major male regulators. However, we have recently 
shown that male factors produced by a non-neuronal secretory tissue that 
surrounds the brain (the fat body) are also required and that courtship is 
significantly compromised when these factors are missing. Efficient 
courtship may therefore require the interaction of endocrine factors with 
specific parts of the nervous system. However, it is unclear how these 
factors either pass through or communicate through the blood brain barrier 
(BBB). 
 
We have performed genetic studies to examine the role of the BBB in the 
control of male courtship. We found that mutations in moody, a BBB-
specific G-protein coupled receptor (GPCR) reduce courtship, and we have 
identified a Gα subunit that is required for courtship in the BBB. 
Furthermore, when we specifically feminized the BBB in otherwise normal 
males by expression of the female specific TRAF protein, we found 
significantly reduced male courtship. Together, these data suggest that 
male-specific proteins and G-protein mediated signaling in the blood brain 
barrier are important for Drosophila male mating behavior. 
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The ability of a drug or its metabolites to leave the lumen of brain 
capillaries and penetrate the brain parenchyma is a general problem during 
drug development for disorders of the central nervous system. Chemical 
analyses of brain homogenates and cerebral spinal fluid do not yield 
complete spatial information required for accurate assessment of a 
molecule’s penetration capability. Visualization of drug related molecules 
using radioisotopes is a powerful method, but requires labeling and lacks 
the ability to resolve possible metabolites. Matrix-assisted laser desorption 
ionization (MALDI) mass spectrometry imaging can directly report the 
locations of drug and related molecules in tissue sections of model 
organisms using solely their accurate mass. MALDI mass spectrometry 
imaging does not require labeling of the drug molecules and can resolve the 
studied drug and its metabolites. The presented study uses mass 
spectrometry for imaging drug penetrance through the blood-brain barrier. 
We find heme signal from mass spectrometry imaging to be a marker for 
visualizing the vasculature and validate this using a fluorescent molecule 
that localizes in the lumen and walls of blood vessels. We use high-
resolution MALDI mass spectrometry for imaging the tumor penetration of 
erlotinib, a model drug, administered at therapeutic levels in mouse 
xenografts of human U87 gliomas.  
 
Brain, liver, and kidney from mice treated for 4 hours with 100 mg/kg 
erlotinib were imaged at up to 50 µm spatial resolution with a high-field 
MALDI Fourier transform ion cyclotron resonance mass spectrometer. A 
total of eight metabolites were observed in liver tissue, representing more 
than half of the reported erlotinib metabolism. The blood-tumor barrier was 
mapped by rendering of the heme molecular ion across the tissue section, 
and the image was compared to an H&E staining of an adjacent section to 
delineate the U87 tumor bulk. The penetration of erlotinib and its active 
metabolites through the blood-tumor barrier were observed, and their 
distribution was assessed. For validation of heme as a marker for blood, 
fluorescein sodium salt (400 mg/kg) was injected in the tail vein of a 
mouse, and the animal was sacrificed after 5 minutes. Tissue sections were 
imaged using a fluorescent scanner, and a MALDI-TOF/TOF mass 
spectrometer. Co-localization of fluorescein and heme from the mass 
spectrometry image suggests that heme is a valid marker of the vascular 
system, and could be used in studies for the development of drugs needing 
to cross the blood-brain barrier.  
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Inflammation initiates the lesions of Multiple Sclerosis (MS) and the 
accumulation of hematogenous inflammatory cells in the central nervous 
system parenchyma is crucial for MS pathogenesis. Chemokines and 
adhesion molecules orchestrate leukocyte accumulation in inflamed tissues. 
Chemokine receptors on defined cell populations(such as monocytes or 
CD45RO+/CD4+ memory T cells) differ strikingly when circulating cells 
are compared with infiltrating cells, suggesting the need of in vitro studies 
to disclose the dynamic modulation of chemokine receptors during 
transmigration. A novel in vitro flow-based BBB model was developed to 
enable bridging the gap between descriptive brain tissue 
immunohistochemistry and target identification for treatment of 
neuroinflammatory diseases. Here, we describe initial studies using this 
model to assay chemokine receptors on T cells, B cells and monocytes 
undergoing BBB transmigration in vitro under flow. Results showed that 
“luminal” CXCL12 (applied to the apical surface of a brain microvascular 
endothelial cell monolayer) stimulated CD4+, CD8+ lymphocyte and 
CD14+ monocyte transmigration, which was susceptible to anti-CXCR4 
neutralizing antibody. Unexpectedly, luminal CXCL12 selectively 
downregulated CXCR4 on monocytes during migration. We also found that 
“abluminal” CCL2 (in the bottom well of the chemotaxis chamber) 
promoted migration of CD4+, CD8+ and CD14+ cells. Monocyte cell-
surface CCR2 protein was downregulated by ligand CCL2. Independent of 
CCL2, monocyte CCR2 mRNA was reduced during the process of 
transmigration, suggesting an explanation for the lack of CCR2 protein on 
tissue-infiltrated monocytes. Results also showed that migrated monocytes 
were CCR5+, compatible with our findings in analyzing MS brain lesions. 
In conclusion, data from tissue staining and BBB models in vitro, taken 
together, will be instrumental for selecting therapeutic targets to modulate 
leukocyte brain infiltration and achieve neuroinflammatory disease control.  
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Central Nervous System (CNS) barriers play a pivotal role in the protection 
and homeostasis of the CNS by enabling the exchange of metabolites while 
restricting the entry of xenobiotics, blood cells and blood borne 
macromolecules. While the blood-brain barrier and blood-cerebrospinal 
fluid barrier (CSF) control the interface between the blood and CNS, the 
ependyma acts as a barrier between the CSF and parenchyma and regulates 
hydrocephalic pressure and metabolic toxicity. Neurocysticercosis (NCC) is 
an infection of the CNS caused by the metacestode (larva) of Taenia solium 
and a major cause of acquired epilepsy worldwide. The common clinical 
manifestations of NCC are seizures, hydrocephalus and symptoms due to 
increased intracranial pressure. The majority of the associated pathogenesis 
is attributed to the immune response against the parasite. The properties of 
the CNS barriers, including the ependyma, are affected during infection 
resulting in disrupted homeostasis and infiltration of leukocytes that 
correlates with the pathology and disease symptoms of NCC patients. In 
order to characterize the role of the ependymal barrier in the 
immunopathogenesis of NCC, we isolated ependyma cells using laser 
capture microdissection from mice infected or mock-infected with the 
closely related parasite Mesocestoides corti and analyzed the genes that 
were differentially expressed using microarray analysis. The expression of 
400 genes was altered. Immune response related genes were verified by 
realtime RT-PCR. Ingenuity Pathway Analysis (IPA) software was used to 
analyze the biological significance of the differentially expressed genes and 
revealed that genes known to participate in innate immune responses, 
antigen presentation and leukocyte infiltration were affected along with the 
genes involved in carbohydrate, lipid and small molecule biochemistry. 
Further, MHC class II and chemokines, including CCL12, were found to be 
upregulated at the protein level using immunofluorescence microcopy. This 
is important, because these molecules are members of the most significant 
pathways by IPA analyses. Thus our study indicates that ependyma cells 
actively express immune mediators and likely contribute to the observed 
immunopathogenesis during infection. Of particular interest is the major 
upregulation of antigen presentation pathway-related genes and 
chemokines/cytokines. This could explain how the ependyma is a 
prominent source of leukocyte infiltration into ventricles through the 
disrupted ependymal lining by way of pial vessels present in the internal 
leptomeninges in murine NCC. 
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Glial cells are important for the formation and maintenance of the Blood 
Brain Barrier in the Central Nervous System (CNS). Much less is known 
however, about the role glial cells play in the regulation of the Blood Nerve 
Barrier in the Peripheral Nervous System (PNS). Following injury or 
demyelinating disease, these barriers break down and inflammatory cells are 
recruited at the injury site. However the molecular mechanisms regulating 
these processes are poorly understood.  
In contrast to the CNS, the PNS can successfully regenerate after injury. 
While Schwann cells, the glia of PNS, are essential to drive the regeneration 
process through their ability to dedifferentiate into progenitor-like cells, the 
recruitment of inflammatory cells is also crucial.  
We have previously shown that the Ras/Raf/Erk pathway is able to induce 
the dedifferentiation of Schwann cells in vitro (Harrisingh et al., Embo J, 
2004). To address whether ERK activation is also sufficient to drive 
Schwann cell dedifferentiation in vivo and investigate the effect of this 
specific signal on the biology of the peripheral nerve, we have generated a 
transgenic mouse model in which Raf kinase can be activated in 
myelinating Schwann cells in the adult nerve. We found that activation of 
Raf in these mice drives demyelination of peripheral nerves in vivo and 
results in severe impairment of motor function. Moreover, we show that 
ERK activation also induces the break down of the Nerve Blood Barrier and 
is consistently accompanied by an inflammatory response and macrophage 
infiltration along the entire nerve despite the absence of injury. Importantly, 
the phenotype of peripheral nerve degeneration is reversible with the period 
of dedifferentiation determined by the period of ERK activation. Moreover 
as part of this regeneration process, the Blood Nerve Barrier is reformed. 
This mouse model provides a powerful system to study the regulation of 
PNS degeneration and regeneration.  
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As the gate keeper of the CNS, the BBB is an important physiological 
structure in regulating and maintaining the environment that is optimal for 
neuronal communication. It is known that in instances of 
neuroinflammation such as in traumatic brain injury (TBI), alteration of the 
BBB is evident. However, what still lacking is a characterization of the 
BBB dysfunction in TBI through evaluation of the tight junctions (TJ). The 
goals of this study were to determine whether alteration to the BBB could 
be detected by morphological changes in the integrity of the TJ as a 
function of injury severity, time and brain region location. Using the 
controlled cortical impact (CCI) mouse model of TBI, mice (n=5 per group) 
were exposed to the following conditions: sham (craniotomy only), mild 
CCI-TBI (1.5 m/s to a depth of 1mm) and moderate CCI-TBI (3.5m/s to a 
depth of 1mm). After seven days post-injury the brain tissue was collected 
and immunofluorescence was performed. First, the pathophysiology of the 
CCI-TBI was confirmed by the presence of gliosis and microglial 
activation, as observed by IBA-1 and GFAP (respectively) intense immune-
reactivity. Neurodegeneration was evaluated using MAP-2 and NeuN which 
indicated decreased neuronal staining in and around the lesion area. Also, 
Greater neurodegeneration was evident in the moderate CCI-TBI along with 
cavitation. Of note, the sham group had no detectable TBI related 
pathology. Assessment of the TJ integrity by ZO-1, occludin and claudin-5 
staining revealed morphological disruptions. As expected, the sham group 
had the characteristic intense and continuous ZO-1 strand-like staining 
pattern. However, a significant number of TJs on the ipsilateral and 
contralateral side of the injury were identified as having 
discontinuous/punctate patterns of staining. Furthermore, many 
microvessels clearly identified by P-glycoprotein and showing no apparent 
gross vessel damage, were found to have little to no ZO-1 staining. As in 
the case with ZO-1, occludin and claudin-5 also showed similar patterns of 
TJ disruption. Recent studies suggest that phosphorylation of occludin and 
claudin 5 are important in contributing to BBB permeability. Using 
phospho-specific antibodies, our results also showed that phosphorylated 
forms of occludin and claudin-5 were apparent at TJs proximal and distal 
from the site of injury. In sum, our study provides a comprehensive analysis 
of the degree of tight junction modification throughout the brain in a mouse 
model of traumatic brain injury. 
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The ubiquitous food-borne bacterium Listeria monocytogenes, though 
ordinarily an agent of gastroenteritis, causes meningitis in immune-
compromised hosts and, rarely, encephalitis in previously healthy hosts. 
The interaction of L. monocytogenes with the mammalian gut epithelium 
has been extensively studied, but less is understood about how L. 
monocytogenes spreads from the digestive tract to infect distal sites, such as 
the central nervous system, and very little is known about how this 
organism is able to breach the blood-brain barrier.  
 
Generally, upon entering a host cell, the bacterium replicates in the 
cytoplasm and expresses the protein ActA, which activates Arp2/3 to 
polymerize actin at the bacterial surface; polarized actin polymerization 
propels the bacterium through the cytoplasm. Eventually, a motile 
bacterium at the membrane of an infected cell protrudes into and is taken up 
by an adjacent uninfected cell; this process, referred to as cell-to-cell 
spread, allows L. monocytogenes to spread through a sheet of epithelial 
cells, without exposure to the extracellular space. 
 
We are examining how L. monocytogenes subverts the barrier properties of 
the vascular endothelium during systemic infection. The most likely 
mechanisms of bypassing the barrier include: direct infection of endothelial 
cells by free bacteria in the bloodstream, infection of endothelial cells via 
cell-to-cell spread from infected circulating immune system cells, and 
transmigration of infected immune system cells across an uninfected 
endothelium. Using fluorescence microscopy, we have confirmed that L. 
monocytogenes can directly infect and spread through a monolayer of 
human umbilical vein endothelial cells (HUVEC) in tissue culture. We have 
demonstrated that L. monocytogenes in infected macrophages and 
macrophage-like cell lines can robustly infect monolayers of HUVEC via 
direct heterotypic cell-to-cell spread, in an ActA-dependent manner. Using 
time-lapse microscopy, we have determined that, in infected macrophages, 
L. monocytogenes form protrusions that may extend for more than ten 
microns before being taken up by an endothelial cell. We are currently 
investigating how astrocyte coculture and blood-brain barrier-like 
differentiation influence the behavior of L. monocytogenes at the 
endothelium. We are also exploring whether macrophage/endothelial cell 
adhesion facilitates bacterial transfer at the endothelium. 
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Hypoxia-ischemia (HI) is a major cause of brain damage in the newborn, where 
inflammation plays a key role in the damaging processes. Growing evidence 
suggest that a group of innate immune receptors, Toll-like receptors (TLRs), are 
involved in the inflammatory response to ischemia. We have shown that LPS-
induced HI brain injury is dependent on MyD88, a TLR adaptor protein, and 
that systemic stimulation with a TLR2 agonist impairs mouse brain 
development, suggesting that TLRs also play an important role in neonatal brain 
damage. The choroid plexus is damaged after HI and responds with an altered 
gene expression after peripheral inflammation induced by LPS. However, data 
is lacking on the role of TLRs in the choroid plexus after neonatal brain 
damage. The purpose of this study was to examine the TLR expression and the 
downstream signaling pathway in choroid plexus after HI alone or in 
combination with different TLR agonists. 
 
Wild type C57/Bl6 mice were subjected to left carotid artery ligation and 10% 
O2 for 50min (HI) on postnatal day 9. The animals were sacrificed 24h after HI 
(n=6-12) and compared to mice not subjected to HI (n=5-8). The brains or the 
choroid plexus from the left lateral ventricles were dissected out and prepared 
for mRNA analysis. The mRNA expression was determined by a TLR pathway-
specific PCR array (SABiosciences). Results are shown as fold regulation 
where the threshold was set to a fold regulation of ±1.5. 
 
At 24h after HI, TLR 3 (1.64), TLR 5 (1.95) and TLR 6 (1.51) were up 
regulated whereas TLR1 (-1.73) was down regulated in the choroid plexus. TLR 
2, 4, 7, 8 and 9 were not regulated. There was also altered gene expression in 
the NFκB signaling pathway downstream of the TLRs (Tirap/mal (-1.56), 
MEKK1 (1.50), NFκB2 (1.55), NFκBib (2.00), Rel (1.64), IL1α (2.10), 
Ptgs2/Cox-2 (3.04), and Ccl2 (5.37)). In the brain, TLR 1 (3.35), TLR 2 (2.27) 
and TLR 7 (2.16) were upregulated, while TLR 5 was down regulated (-1.76) 
and TLR 3, 4, 6, 8 and 9 did not change. Changes in gene expression in the 
choroid plexus after stimulation with different TLR agonists with or without HI 
are under investigation. 
 
Conclusion: The mRNA expression of several TLRs and their downstream 
signaling molecules was altered in the neonatal brain and in choroid plexus after 
HI. However, the response in choroid plexus was completely different to the 
changes in the brain. This is the first demonstration of TLR regulation in the 
choroid plexus after neonatal HI. The data suggest that specific TLRs may be 
functioning in choroid plexus after HI, which differ from those in the rest of the 
brain. 
 25 
BRAIN MICROVASCULAR ENDOTHELIAL CELL 
HYPERPERMEABILITY INDUCED BY CASPASE-3 ACTIVATION 
 
Binu Tharakan, Devendra A Sawant, Felicia A Hunter, Ed W Childs  
 
Texas A&M Health Science Center College of Medicine & Scott and White 
Hospital, Surgery, Temple, TX, 76504 
 
The blood brain barrier (BBB) integrity depends mainly on the integrity of 
the tight junction proteins (TJPs) of the brain microvascular endothelial 
cells. We hypothesized that the increased mitochondrial ROS formation 
following ischemic-stroke reperfusion and subsequent activation of caspase-
3 will lead to the proteolytic cleavage of the TJPs, resulting in barrier 
disruption, hyperpermeability and brain edema. Our objective was to study 
if oxygen and glucose deprivation followed by reoxygenation (OGD-R) 
would disrupt the TJPs, ZO-1 and occludin and lead to brain microvascular 
endothelial cell hyperpermeability under in vitro conditions. Rat brain 
microvascular endothelial cell (RBMEC) monolayers grown either on 
Transwell plates, chamber slides or on regular dishes were subjected to 
OGD-R in presence or absence of a capase-3 inhibitor Z-DEVD-FMK. The 
OGD-R was achieved by replacing the regular medium with a glucose free 
medium and exposing the cells to an anaerobic chamber at 37°C. The OGD-
R period was terminated by replacing the glucose free medium with the 
regular medium and placing the cells in a 5%CO2/95% air incubator. The 
monolayer permeability was studied by using FITC-dextran flux across the 
monolayer. The mitochondrial ROS formation was studied using 
dihydrorhodamine 123 and the mitochondrial transmembrane potential 
(MTP) by the JC-1 method. The integrity of the tight junctions was 
determined by immunofluorescence of ZO-1 and occludin. The caspase-3 
activity was determined using a fluorometric assay. OGD-R induced, 
hyperpermeability of the monolayer that was inhibited by the caspase-3 
inhibitor Z-DEVD-FMK (p<0.05). OGD-R, induced mitochondrial ROS 
formation, decreased the MTP, and increased caspase-3 activity 
significantly (p<0.05). The control cells showed junctional continuity of 
ZO-1 and occludin whereas the cells exposed to OGD-R showed 
discontinuity of junctional staining and intercellular gap formations that was 
prevented by Z-DEVD-FMK. Our results suggests that, the increased 
mitochondrial ROS formation following OGD-R and subsequent activation 
of caspase-3 led to the proteolytic cleavage of ZO-1 and/or occludin 
resulting in barrier disruption and hyperpermeability. This might serves as a 
mechanism for ischemic-stroke reperfusion induced BBB disruption and 
brain edema.  
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In the mammalian brain the passage of molecules from the blood to the 
brain parenchyma is tightly controlled in order to maintain an environment 
necessary for proper neuronal function. In the central nervous system the 
main physical barrier is formed by endothelial cells. Other suggested 
components of the blood-brain barrier include extracellular matrix 
components, astrocytes, and pericytes. However, the relative contribution of 
the different blood-brain barrier building blocks remains largely unknown. 
In this study, we have analyzed the role of pericytes at the neurovascular 
unit in the adult animals. In order to do this we have generated two viable 
pericyte-deficient mouse models. We show that pericyte-deficiency does 
not affect the endothelial cell differentiation specific for the central nervous 
system, and polarization of endothelial cells. Formation of endothelial 
adherens and tight junctions does take place in pericyte-deficient mice. 
However, pericyte-deficient animals show accumulation of intravenously 
injected tracers (with different molecular weigths) in the brain parenchyma 
and leakage of tracers correlates with the degree of pericyte-deficiency. 
Administration of broad spectrum tyrosine kinase inhibitor Imatinib 
abolishes the extravasation of tracers into the brain parenchyma in pericyte-
deficient animals. We also show that pericytes are important for astrocyte 
end-feet polarization. In conclusion, we demonstrate the importance of 
pericytes for the integrity of the blood-brain barrier and organization of the 
astrocyte end-feet in vivo. 
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Tight control of vascular permeability is essential for normal brain function 
but little has been known about the molecular basis of blood-brain barrier 
(BBB) formation and maintenance. It is well established however, that 
during developmental brain angiogenesis and in the mature brain the 
specific brain milieu, and in particular neural progenitors and astrocytes, is 
responsible for the induction and maintenance of BBB characteristics in 
endothelial cells (ECs). Only recently others and we provided first evidence 
that endothelial Wnt/beta-catenin signaling is necessary for brain 
angiogenesis and the induction of BBB characteristics. Endothelial specific 
beta-catenin signaling was observed during embryonic BBB development 
and its postnatal maturation but becomes largely silenced in the adult. 
Endothelial specific stabilization of beta-catenin in vivo and in primary 
brain ECs in vitro enhanced barrier maturation, and induced claudin-3 
expression and BBB-type tight junction formation evidenced by freeze-
fracture preparations. In turn, endothelial deletion of beta-catenin led to a 
rapid loss of barrier properties in vivo and in vitro. 
Presumably, brain endothelial cells, once their barrier properties have been 
established, continuously need by now unknown „cues“ to maintain BBB 
characteristics. This becomes particularly apparent under pathological 
conditions in the brain when BBB function is disturbed. Specifically, in 
glioblastoma (astrocytoma grade IV) the significant loss of BBB function in 
brain capillaries promote the severe symptoms of brain edema, ultimately 
leading to clinical complications and death of the patient. 
We now provide evidence that in a murine brain tumor model, beta-catenin 
stabilization in angiogenic glioblastoma vessels decreased tumor 
angiogenesis and growth. In turn, inhibiting Wnt signaling in these tumors 
significantly increased vascularity and size of the tumors. Additionally, 
augmented Wnt/beta-catenin signaling in the tumor endothelium prevented 
vascular hyper-permeability, suggesting a new potential therapeutic avenue 
for limiting the devastating effects of tumor induced BBB breakdown. 
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We quantified blood-brain barrier (BBB) permeability with the rate constant for 
influx (Ki) across the BBB with α-aminoisobutyric acid (AIB) in fetal, neonatal 
and adult sheep. Although the permeability of the BBB measured with AIB is 
relatively low during fetal and neonatal development, the ovine fetus and 
neonate exhibited ontogenic decreases in barrier permeability. The low 
permeability measured with AIB suggests that a functionally tight barrier is 
present from very early in gestation. We also examined the developmental 
regulation of tight junction (TJ) proteins in sheep and found that occludin, 
claudin-1, claudin-5, ZO-1, and ZO-2 were expressed very early in fetal life and 
throughout ovine development. The patterns of expression varied amongst TJ 
proteins. In general, the transmembrane protein was higher in the fetuses than in 
newborn and adult sheep, and ZO-1 was highest in newborn sheep and ZO-2 
higher in newborn and adult sheep than fetuses. The expression patterns of 
individual TJ proteins do not necessarily reflect ontogenic changes in BBB 
permeability with development, rather, the proteins of the TJ complex work 
together to form an effective barrier. The pituitary-adrenal cortical axis matures 
during fetal development. We postulated that the pituitary-adrenal cortical axis 
functions as a physiological regulator of BBB function in the fetus. We showed 
that both increases in gestation and in plasma cortisol contributed to the 
decreases in BBB permeability during fetal development. Maternally 
administered antenatal glucocorticoids are used to accelerate fetal maturation. 
Antenatal glucocorticoids reduce the incidence of intraventricular hemorrhage 
and may enhance brain microvascular integrity in the fetus. We showed that 
antenatal glucocorticoids reduce BBB permeability in the ovine fetus at 60%, 
70%, and 80% of gestation, but not at 90% of gestation or in newborn lambs. 
The age-related differential responsiveness of the fetal and neonatal barrier to 
exogenous glucocorticoids are most likely to related to the effects of increases 
in endogenous steroids on BBB maturation. We also showed that maternal 
glucocorticoid treatment increases in occludin, claudin-1, and claudin-5 
expression in select fetal brain regions and that decreases in permeability 
correlate with the increases in claudin-1 and claudin-5, but not occludin. 
Therefore, this common maternal treatment affects both the functional and 
molecular characteristics of the fetal BBB. We conclude that BBB function 
develops early in fetal gestation, the structural proteins of tight junctions are 
present very early in ovine development, and endogenous increases in 
glucocorticoids are associated with decreases in BBB permeability, and that 
maternal glucocorticoid treatment decreases BBB permeability and increases TJ 
protein expression in the fetus.  
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Endothelial cells in the body display a remarkable diversity and are 
perfectly adapted to the needs of the underlying tissue. One of the best 
examples of specific endothelial cell function is found in the blood–brain 
barrier (BBB) which is required for optimal brain homeostasis and neuronal 
performance. Brain capillaries are surrounded by and closely associated 
with several other cell types, including the perivascular endfeet of 
astrocytes, pericytes, microglia and neuronal processes that have been 
shown to contribute to barrier function. In particular, astrocytic endfeet are 
in close proximity to the endothelial cell plasma membrane, are separated 
only by the basal lamina and have been implicated in the induction of the 
BBB.  
Perturbations of BBB function are hallmarks of a variety of brain diseases. 
On the other hand, multiple efforts are focused on developing strategies to 
overcome the BBB and to effectively deliver active drugs to the brain. 
Understanding the mechanisms involved in the regulation of the blood-brain 
barrier may therefore open novel therapeutic avenues for treatment of 
neurological diseases. Yet, little is known regarding the molecular 
mechanisms that support the function of the BBB.  
Using a combined genetic and bioinformatics approach, we uncovered a 
novel mechanism by which astrocytes mediate BBB function, i.e. through 
the activity of a new class of gene regulators called microRNAs. 
microRNAs regulate gene expression by binding to partially 
complementary sites in the 3’ untranslated regions (UTR) of target genes, 
thereby causing degradation or translational repression. The role of 
microRNAs in endothelial biology is emerging and several microRNAs 
have been implicated in peripheral endothelial cell function in vitro and in 
vivo. It was not known whether microRNAs through their potential target 
genes play a role in blood-brain barrier function.  
We believe that detailed knowledge about these genes will allow us to 
design in the future novel therapeutic approaches for several neurological 
diseases in which blood-brain barrier repair is required or controlled 
opening is needed for effective treatment in for example brain cancer. Our 
latest findings will be presented.  
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During inflammation, increased production of cytokines by activated 
leukocytes and/or central nervous system (CNS) resident cells has been 
shown to alter the phenotype and function of cerebral microvascular 
endothelial cells leading to blood-brain barrier (BBB) dysfunction. 
MicroRNAs (miRs) are endogenous non-coding small RNAs recognised as 
potent post-transcriptional regulators of gene expression by silencing their 
mRNA targets. Deregulated miR levels have been demonstrated in several 
pathologies although their role in the pathogenesis of CNS inflammatory 
disorders remains to be elucidated. We hypothesised that endothelial miRs 
regulate CNS inflammation, by modulating blood-brain barrier permeabilty. 
To investigate this, we have determined changes in the pattern of both miR 
and mRNA expression induced by pro-inflammatory cytokines in an 
immortalized human cerebral microvascular endothelial cell line, 
hCMEC/D3 by microRNA and mRNA microarray respectively. Treatment 
with TNF-α and IFN-γ altered mRNA levels of 706 genes more than 2 fold 
over control levels, with the highest increases (>30 fold) observed for 
chemokines and adhesion molecules. We then identified 13 up-regulated 
and 122 down-regulated miRs in hCMEC/D3 cells, following treatment 
with cytokines. We selected miR-155 for further analysis, as it showed a 
rapid increase following cytokines stimulation. Transfection of brain 
endothelial cells with miR-155 induced a moderate increase in leukocyte 
adhesion and paracellular permeability which was concurrent with altered 
mRNA levels of genes associated with tight junctions and regulation of the 
actin cytoskeleton. We are currently investigating the putative mRNA 
targets of miR-155 in human brain endothelium implicated in BBB 
dysfunction following inflammation. Understanding the role of microRNAs 
in inflammation might help to identify novel therapeutic targets for CNS 
inflammatory disorders. 
 31 
MONOCLONAL ANTIBODY BINDING TO UNIQUE STRUCTURES 
(LOOPS D AND F) OF BACE1 INHIBITS Β-SECRETASE ACTIVITY 
IN VIVO  
 
Lujia Zhou1,2, Lucia Chávez-Gutiérrez1,2, Wim Annaert1,2, Patrick C May3, 
Eric Karran4, Bart De Strooper1,2  
 
1VIB, Department for Molecular and Developmental Genetics, Leuven, 
3000, Belgium, 2KULeuven, Center for Human Genetics, Leuven, 3000, 
Belgium, 3Eli Lilly, Neuroscience Discovery Research, Indianapolis, IN, 
46285, 4Johnson and Johnson, Neuroscience Discovery Research, Beerse, 
2340, Belgium 
 
β-Secretase (BACE1) is an attractive drug target for Alzheimer’s disease. 
The design of clinical useful inhibitors targeting the active-site of BACE1, 
has however been extremely challenging. To identify potentially alternative 
drug targeting sites we have generated a panel of BACE1 monoclonal 
antibodies (mAb) that interfere with BACE1 activity in various assays and 
determined their binding sites. We identified mAb 5G7 as a potent BACE1 
inhibitor in enzymatic assays (IC50 ~0.47nM), that displayed no inhibitory 
effect in primary neurons. The mAb 5G7 binds to a surface helix 
comprising residues 299-312 and the epitope is “hidden” when BACE1 is 
membrane-anchored. Mutagenesis of this helix strongly reduced BACE1 
ectodomain shedding. A second mAb, 1A11, inhibited BACE1 activity 
potently in vitro (IC50 ~0.76nM), and in primary neurons (EC50 ~1.8nM). 
It blocked BACE1 activity in vivo in mouse brain after stereotaxic 
injection. Paradoxically mAb 1A11 increased the activity of BACE1 
towards small substrates in vitro. It binds to the adjacent loops D and F of 
BACE1, which together with helix A, distinguish BACE1 from BACE2 and 
other aspartic proteases. These structures are highly flexible and flank the 
active-site cleft of BACE1. Mutagenesis of loop F and helix A decreased or 
increased BACE1 activity, suggesting that these regions are modulating 
BACE1 activity. Our work suggests alternative promising drug targeting 
sites for BACE1 inhibition and should stimulate alternative development of 
small compounds that target these sites. 
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Even early in development, the brain and spinal cord show evidence of 
function eg breathing and limb movements. Still earlier, complex processes 
are involved in cell differentiation from precursor cells to form neurons, 
pericytes & glia. However, it has been widely believed for decades that 
brain develops in an environment not much different from the embryo as 
whole, exemplified by terms such as “leaky” blood-brain barrier. Although 
more a matter of philosophy than science, it is worth considering why this 
belief has persisted and what are the consequences for understanding the 
relation between specific features of the local environment of brain and 
particular features of its development and pathologies that may result from 
impaired brain barrier function. The belief seems to lie in a teleological 
argument that the developing brain would not “need” a protective 
mechanism as provided by the blood-brain barrier in adults, because of 
protection by the placenta, as explicitly stated by Barcroft (1938, The brain 
and its environment. Yale Univ Press) and supported by careful selection of 
experimental evidence. I shall briefly review some older evidence, which 
should have led to acceptance of the hypothesis that the brain develops and 
functions within its own well-defined internal environment. I shall deal 
mainly with key experiments performed recently, which provide convincing 
evidence that the main structural and functional features of blood-brain 
barrier mechanisms develop as soon as cerebral blood vessels (blood-brain 
barrier) and choroid plexuses (blood-CSF barrier) differentiate (Ek et al 
2006, J Comp Neurol 496, 13-26; Daneman et al 2010, Nature. Oct 13. 
doi:10.1038/nature09513). This recent work also lays to rest the 
misconception that astrocytes are involved in tight junction formation in the 
early stages of vascularisation of the brain. There are several serious 
consequences of this longstanding belief in a leaky or immature blood-brain 
barrier. It has inhibited serious research on properties of the real internal 
environment of developing brain. Until recently there has been little 
consideration of the possibility that pathological conditions in embryos 
might affect blood-brain barrier properties and lead to abnormal brain 
development (Stolp & Dziegielewska, 2009, Neuropath Appl Neurobiol 35, 
132-146). It seems likely that this belief has delayed serious consideration 
of whether the protective mechanisms against drugs and toxins so 
prominent in adult brain, may exist in embryos (Ek et al 2010). This has 
important implications for clinical practice and formal regulation of use of 
drugs in pregnant women and newborn infants. 
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The blood-brain barrier (BBB) is an effective gatekeeper that tightly 
regulates trafficking of molecules between the bloodstream and neuronal 
parenchyma. Although many substances are restricted from crossing the 
BBB, specific molecules can traverse the BBB through both receptor- and 
carrier-mediated transport mechanisms. Accordingly, the BBB gene 
expression profile is markedly distinct from that of the peripheral 
vasculature, specifically expressing molecules that drive both low 
paracellular/transcellular movement and exchange of essential nutrients and 
neurotoxic waste. While many of these BBB-specific 
transporters/molecules have been functionally characterized, the distinct 
signaling events that drive central nervous system (CNS) angiogenesis and 
barriergenesis are just beginning to be understood. To this end, we have 
utilized two complementary strategies towards a better understanding of 
BBB development, maturation, and maintenance: (i) Expression profiling of 
the murine BBB to identify new molecules enriched at the BBB along the 
developmental timeline, and (ii) a subsequent morpholino-based zebrafish 
screen to determine the functional relevance of these BBB-specific 
molecules. To date, we have identified several signaling receptors that drive 
BBB-specific development in both zebrafish and mouse models, including 
members of the TNFR family. These findings allow us to add novel 
molecular components to the known signaling mechanisms that drive CNS 
angiogenesis and barriergenesis. 
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Early in development cerebrospinal fluid (CSF) in the fetal brain contains 
very high concentrations of protein generated by their transfer from plasma 
across choroid plexus epithelial cells (Johansson et al., Bioessays 2008, 
30:237). Previous studies demonstrated that about 10% of plexus cells in 
neonatal opossum (Monodelphis domestica) are involved in unidirectional 
transfer of plasma proteins from blood to CSF (Liddelow et al., Eur J 
Neurosci 2009, 29:253). We have investigated the sensitivity of this transfer 
mechanism by altering circulating levels of individual proteins in the 
plasma. Control of protein transfer across plexus epithelial cells was 
investigated by intraperitoneal injection of adult plasma into opossum pups 
at different postnatal (P) ages. Concentration of total and individual plasma 
proteins were estimated and volumes of the lateral ventricular system 
measured. Injections of adult plasma resulted in increased total protein 
concentration in the CSF within 6-24 hours at P65 and P110, but not at P9 
due to ventricular expansion at this age only. Protein content in CSF 
increased at all 3 ages. Albumin and hemopexin increased in CSF at P9 and 
P65, but not in adults. The number of choroid plexus cells immunopositive 
for individual proteins mirrored these changes. AFP concentration did not 
change at P9 (the only age it was detected), however the number of cells 
decreased. Injection of a foreign protein, bovine fetuin, also resulted in an 
increase in CSF protein content and the exogenous protein was detected 
both in the CSF and within protein-transferring plexus cells. Bovine fetuin 
appeared to displace some endogenous proteins – hijacking the native 
protein transport system of the choroid plexus. These results suggest that 
there may be specific, developmentally regulated, transporters responsible 
for protein transfer across the blood/CSF barrier which may be important 
for some features of brain development. This raises the possibility of 
designing delivery systems from the blood to CSF and thence the brain via 
the choroid plexus epithelial cells.  
The authors acknowledge funding support from the Neurobid Consortium, 
funded by the 7th Framework Program (EU) and National Health and 
Medical Research Council (Australia).  
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Integrins are heterodimeric cell-surface proteins that regulate cell growth, 
migration and survival. It was previously shown that glial-derived integrin 
αvβ8 binds and activates latent transforming growth factor-β (TGFβ), and 
that loss of integrin β8 from the developing brain neuroepithelium 
(β8nescre mice) leads to brain hemorrhage. Based on this work, we 
analyzed TGFβ activation and vascular phenotypes preceding hemorrhage 
in β8nescre mice, TGFβ1 ligand knockout mice, and mice with conditional 
deletion of TGFβ receptor in endothelial cells and pericytes. We report that 
TGFβ activation is spatially restricted to the ventral germinal matrix 
neuroepithelium, and that β8;nescre mice develop vascular dysplasia and 
hemorrhage coincident with loss of domain-specific TGFβ activation. 
Furthermore, we show that mice deficient in TGFβ signaling in endothelial 
cells or pericytes recapitulate key aspects of the β8nescre phenotype. We 
have therefore uncovered a pathway in which the loss of integrin-mediated 
activation of latent TGFβ causes vascular specific morphogenic changes 
leading to germinal matrix hemorrhage. The remarkable similarity between 
the phenotypes in β8 and TGFβ mutants and human infants with germinal 
matrix hemorrhage suggests that a functional alteration in the TGFβ 
activation pathway may affect susceptibility to this disease. 
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Normal brain function depends upon the proper structure and function of 
the vascular system. One unique feature of the blood vessels in the central 
nervous system compared to the blood vessels in the rest of the body is the 
blood brain barrier (BBB), a highly specialized brain endothelial structure 
composed of tight junctions and specialized transporters. In concert with 
pericytes and astrocytes, the BBB protects the brain from various toxins and 
pathogens and provides the proper chemical composition for synaptic 
transmissions. Emerging evidence demonstrates that the BBB is formed 
much earlier than previously thought. However, the timing of its formation 
and the mechanisms governing the initial formation of the BBB are still 
largely unknown. Here we focus on the developmental process of blood 
vessel network formation in the CNS, to investigate the relationship 
between the BBB formation and vascular network formation. Most of the 
extensive vessel networks are formed through angiogenesis, a process 
where new vessels form by sprouting from existing vessels. This process 
begins when select endothelial cells called “tip cells” arise from a distinct 
site on the mother vessel and sprout towards angiogenic cues in the 
environment. Neighboring “stalk cells” proliferate and add to the new 
sprout. When two new sprouts meet, a connection is formed, augmenting 
the existing network. Reiteration of the tip cell selection, sprouting, and 
connecting events is the basis for building a sophisticated vascular network. 
We hypothesize that BBB begins to form as soon as two neighboring tip 
cell filopodia connect , i.e. vascular anastomosis occurs. We test this 
hypothesis using mouse genetics and in vitro assays. We aim to understand 
the temporal, spatial, and molecular interactions between BBB formation 
and angiogenesis process.  
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Precise regulation of cell-cell and cell-extracellular matrix (ECM) adhesion 
and communication within neurovascular units is essential for proper 
development and homeostasis of the blood-brain barrier (BBB). Integrins 
are cell surface receptors for ECM proteins and many integrins are 
expressed in neural and vascular cell types; however, their adhesion and 
signaling roles in neurovascular unit development and physiology remain 
mostly uncharacterized. We have used Cre/lox technology to analyze the 
roles for one integrin, αvβ8, which is expressed in perivascular radial glial 
cells and astrocytes where is binds to the ECM-associated forms of latent 
TGFβs. Selective ablation of αv or β8 integrin genes in glial cells leads to 
CNS-specific vascular pathologies, including abnormal endothelial cell 
growth and sprouting in the brain and retina, hemorrhage and premature 
death. Knockout mice that survive to adulthood display multiple vascular 
abnormalities in the brain and retina, including defective vascular basement 
membrane integrity, compromised BBB permeability and perivascular 
astrogliosis. Adult mutants also develop hemorrhage-induced 
hydrocephalus and die by six months of age due to related neurological 
deficits. These neurovascular phenotypes are due, in part, to impaired αvβ8 
integrin-mediated adhesion to latent TGFβs in vascular basement 
membranes and subsequent activation of TGFβ signaling pathways in 
endothelial cells. Collectively, these data reveal essential roles for αvβ8 
integrin in regulating neurovascular unit development and physiology in the 
embryonic and post-natal mouse brain. 
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Reduction in blood flow is known to induce blood vessel regression. 
However, genetic perturbations that are effective in inducing the regression 
of high flow conduit vessels are largely unknown. Here we demonstrate 
rapid regression of high-flow large vessels upon repression of constitutively 
active Notch4 (Notch4*) in endothelial cells, as revealed by recurring high-
resolution two-photon imaging in live mouse brains. Notch4* arterialized 
vein segments, which then abnormally connected to arteries, resulting in 
arteriovenous shunting. Turning off Notch4* led to specific regression of 
the established high-flow arteriovenous connections. Notch repression 
initiated prompt reorganization of endothelial cells, vessel constrictions, and 
blood flow reductions in regressing vessels. The involution of arteriovenous 
shunts returned shunted blood to perfusing vessels, reversing tissue hypoxia 
and neuronal dysfunction. Our data provide direct, in vivo evidence that 
Notch signaling can exert dominant effects over hemodynamics in 
regulating arterial structure. Our findings imply that Notch inhibition may 
potentially lead to degeneration of arteriovenous shunts, whereas Notch 
activation may improve arterialization of vein grafts in the treatment of 
arterial occlusive diseases.  
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The blood protein fibrinogen as a ligand for integrin receptors functions as 
the molecular nexus of coagulation, inflammation and immunity. 
Fibrinogen extravasates in the nervous system after injury or disease 
associated with vascular damage or blood-brain barrier (BBB) disruption. In 
multiple sclerosis (MS), perivascular demyelination is accompanied by 
increased vascular permeability resulting to extensive deposition of fibrin. 
Our studies in animal models for MS have demonstrated that fibrinogen is 
not merely a marker of BBB disruption, but a mediator of 
neuroinflammation. Fibrinogen mediates pro-inflammatory functions in the 
nervous system by activating the Mac-1 integrin receptor (also known as 
CD11b/CD18 and complement receptor 3) in microglial cells. In vivo 
imaging in the mouse spinal cord using two-photon microscopy shows that 
microglia perform constant surveillance of blood vessel walls in myelinated 
areas. Pharmacologic or genetic disruption of the fibrinogen/Mac-1 
interaction suppresses neurologic symptoms, inflammation and 
demyelination in Experimental Autoimmune Excephalomyelitis (EAE), a 
model of MS. Because blocking fibrinogen/Mac-1 interaction affects the 
proinflammatory but not the procoagulant properties of fibrinogen, 
strategies to target fibrinogen receptors within the tissue microenvironment 
could reveal selective and disease-specific agents for therapeutic 
intervention in neuroinflammatory diseases. 
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Arterial ischemic stroke in the neonate occurs at a rate similar to that in 
adults but immaturity affects both injury and recovery. The blood-brain 
barrier (BBB) may contribute to the age-related injury patterns but little is 
known about BBB after neonatal stroke. Emerging evidence suggests that 
the early postnatal BBB is not as permeable as commonly thought. Tight 
junctions (TJ) are present early in embryonic development, restricting 
entrance of proteins into the brain, and by birth BBB is functional with no 
fenestrations. Objective: Using an age-appropriate rodent model that 
mimics arterial stroke in term babies, we asked if BBB is disrupted by 
cerebral ischemia in immature animals. Methods: Postnatal day 7 (P7) and 
adult rats were subjected to a transient 3hr middle cerebral artery occlusion 
(MCAO). Diffusion-weighted MRI was used to identify injured animals and 
guide in tissue dissection. TJ protein expression (Western Blot; fold 
increase, injured/contralateral), paracellular diffusion (Evans Blue assay), 
Gd-enhanced T1W MRI, cytokine levels (multipex), and histological 
outcome were determined 24hr after reperfusion. A neutralizing anti-CINC-
1 antibody was administered before MCAO. Results: In adult, Evans Blue 
showed a 14-fold increase in albumin extravasation in the injured caudate 
and a 5-fold increase in the cortex whereas in the neonates increase was 2-
fold. The pattern of TJ expression changes differed between neonatal and 
adult rats. A significant 2 fold increase in claudin-5 expression was seen in 
injured cortex of neonates whereas expression remained unchanged in 
adults. Occludin expression tended to increase in neonatal but decreased in 
adult rats. ZO-1 expression was unaffected in neonatal but was significantly 
reduced (0.5 fold) in adult rats. In P7 rats, Gd-enhancement (T1W-MRI) 
was <10%, and neutrophil extravasation was low 1-24hr after reperfusion 
despite the marked accumulation of inflammatory cytokines, including IL-
1β and CINC-1. CINC-1 neutralization exacerbated injury and affected TJ 
protein expression. Conclusions: Paracellular diffusion is markedly 
disrupted in adult but not in neonatal acute stroke. The better preserved 
neonatal BBB is associated with more preserved TJ and low neutrophil 
extravasation. Ischemia-induced increase of neutrophil chemoattractants 
likely contributes to endogenous defenses. Understanding the mechanisms 
that contribute to BBB integrity after neonatal stroke is critical in the search 
for new therapeutic targets. 
Support: AHA 0655236Y, NS44025, NS55915 
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Despite numerous animal drug trials targeting different pathogenic pathways, 
pharmacological approaches to cure the mutant mouse that models amyotrophic 
lateral sclerosis (ALS) have so far failed. This suggests either yet undefined 
crucial pathogenic mechanisms or a frank pharmacoresistance to treatments in 
these mice. Drug transporters influence pharmacokinetics and 
pharmacodynamics; among different drug transporter systems, the multi-drug 
resistant efflux transporter P-glycoprotein (P-gp; mdr1) extrudes a broad range 
of xenobiotics from cells and confers chemoresistance and a poor clinical 
outcome. In addition to normal expression in several peripheral tissues, P-gp is 
expressed in the central nervous system with predominant localization to 
capillary endothelial cells and, to a lesser extent, parenchymal and perivascular 
astrocytes of the blood brain/blood cerebrospinal fluid barriers (BBB/BCSF). P-
gp is up-regulated under certain neuropathological conditions such as 
intractable epilepsy and in rodent models of temporal lobe epilepsy, and this 
appears to be regulated by the excessive glutamate release occurring in these 
seizure episodes. Kainate-triggered seizures induce neuronal P-gp expression 
and up-regulate P-gp in BBB endothelial cells and astrocytes, but P-gp 
expression, localization, and distribution under pathological conditions of the 
spinal cord are virtually unexplored. Although glutamate excitotoxicity and 
neuroinflammation are also components of ALS, drugs that increase glutamate 
clearance in the ALS mouse have been largely unsuccessful. We previously 
reported consistent yet transient effects of nordihydroguiaiaretic acid (NDGA), 
a glutamate uptake enhancer, as well as a disease-driven up-regulation of spinal 
cord P-gp in ALS mice, suggesting that this and other pharmacotherapeutic 
failures may result from acquired, P-gp-mediated pharmacoresistance. Here we 
investigate P-gp cellular localization and expression in the spinal cord of ALS 
mice throughout disease progression. We find that P-gp is expressed in 
motoneurons and that P-gp expression increases in ventral spinal cord 
astrocytes throughout disease. We also examined P-gp expression in spinal cord 
homogenate from humans and report that P-gp is elevated in ALS patients. 
Thus, P-gp expression in spinal cord parenchyma may impart overt 
pharmacoresistance to ALS affected cells and account for the poor therapeutic 
effect observed in multiple ALS clinical drug trials. P-gp up-regulation in 
diseased CNS parenchyma may be a cellular mechanism to extrude increased 
levels of endogenous toxins resulting from the disease. 
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Sepsis and jaundice, by elevated levels of unconjugated bilirubin (UCB) are 
two common conditions in neonatal disease. There are studies on 
endothelial cells showing that lipopolysaccharide (LPS) modifies the 
integrity of confluent monolayers. UCB is known for its potential 
neurotoxity, although the mechanisms underlying its access to the brain 
remain unclear. In fact, there is only one study on the effects of UCB on 
bovine brain endothelial cells where it was shown that UCB induces 
apoptosis. Furthermore, the effects of both compounds on endothelial cells 
have also never been investigated. In this study we used a monolayer of rat 
brain microvascular endothelial cells (RBMEC) as a simplified model of the 
BBB in order to investigate whether these compounds (i) alter RBMEC 
viability; (ii) compromise BBB integrity; (iii) and impair BBB function. 
Primary cultures of RBMEC were exposed to 1 µg/ml LPS with or without 
50 µM purified UCB in the presence of 100 µM human serum albumin, 
used to solubilize UCB, for 4 h and 24 h at 37ºC. Cell viability was 
evaluated by determining lactate dehydrogenase (LDH) release. Barrier 
integrity was studied in terms of permeability to sodium fluorescein (Na-F) 
(MW: 376 Da), transendothelial electrical resistance, as well as changes in 
tight junction proteins by immunostaining. In addition, we evaluated P-
glycoprotein (P-gp) activity. Exposure of RMBEC to LPS appeared to have 
no significant effect on cell viability, whilst incubation with UCB already 
induced death upon 4 h treatment. Transendothelial electrical resistance was 
affected by LPS mostly at 4 h treatment, while UCB caused a major 
decrease after 24 h. Accordingly, LPS-induced leakiness to Na-F was more 
marked at 4 h, whereas the increased permeability due to UCB augmented 
along exposure. Tight junctions were altered both by LPS and UCB. As for 
P-gp activity, LPS did not appear to have any effect, whereas UCB 
impaired its activity for the time studied (24 h). In conclusion, the observed 
effects produced by UCB and LPS on brain endothelium may have 
significant implications in the first days of life by potentially allowing the 
influx of the neurotoxins to the brain and consequent injury. 
 
Funded by FCT-PTDC/SAU-FCF/68819/2006 
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TUMOR NECROSIS FACTOR-Α TRIGGERS A CYTOKINE CASCADE 
YIELDING POSTOPERATIVE COGNITIVE DECLINE 
 
Niccolo Terrando1,2,3, Claudia Monaco2, Marc Feldmann2, Mervyn Maze1,3  
 
1University of California San Francisco, Anesthesia and Perioperative Care, 
San Francisco, CA, 94143, 2Imperial College London, Kennedy Institute of 
Rheumatology, London, W6 8LH, United Kingdom, 3Imperial College 
London, Anesthetics, Pain Medicine and Intensive Care, London, SW10 
9NH, United Kingdom 
 
Surgical trauma may lead to cognitive decline. Activation of the innate 
immunity, cytokines, and neuroinflammation are putative mechanisms to 
underlie cognitive dysfunction. Yet, no successful therapies exist to prevent 
this complication after surgery. Here we report on the key role of tumor 
necrosis factor-α (TNF) as an early initiator and possible therapeutic target 
for the prevention of postoperative cognitive dysfunction (POCD).  
 
Adult C56BL/6J, MyD88-/-, IL-1-/-, and TLR4-/- male mice were 
randomly assigned into groups: 1) untreated animals; 2) general anesthesia 
(GA) with isoflurane + buprenorphine for analgesia; 3) stabilized tibial 
fracture under GA and analgesia; 4) anti-TNF prophylaxis 18 h prior to 
surgical intervention. Separate cohorts of mice per group were assessed for 
plasma and hippocampal cytokines (ELISA), microglial activation, and 
hippocampal dependent memory using trace fear conditioning.  
 
Preemptive targeting of TNF with the administration of a blocking 
monoclonal antibody (ab) before surgery significantly reduced systemic IL-
1β and IL-6 at 6 and 24 hours following tibial surgery. TNF ab also reduced 
surgery-induced expression of IL-1β in the hippocampus and subsequent 
microglial activation. Postoperative decline in the contextual fear response 
was significantly ameliorated following TNF ab prophylaxis (p<0.05 vs 
surgery). Delaying administration of ab until 1 h postoperatively was 
ineffective. As anti-TNF prophylaxis did not fully abolish the inflammatory 
response, we explored alternative pathways in innate immunity. MyD88-/- 
and IL-1-/- mice showed elevation in TNF similarly to wild-types, however 
they were both protected from cognitive decline. Combination of anti-TNF 
prophylaxis in MyD88-/- completely abrogated the systemic inflammatory 
response. Addressing the role of pattern recognition receptors, TLR4-/- 
were not protected from postoperative cognitive decline, and resulted in 
elevations of IL-1β and IL-6 both systemic and centrally.  
 
These data demonstrate that preemptive targeting of TNF as an early marker 
during post-surgical inflammation suppresses generation of IL-1, preventing 
neuroinflammation and cognitive decline. Systemic cytokines appear as key 
mediators in mediating further neuroinflammation both through MyD88-
dependent and independent pathways. 
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GENE EXPRESSION ANALYSES OF PIAL VESSELS OF THE BLOOD 
BRAIN BARRIER DURING MURINE NEUROCYSTICERCOSIS  
 
Pramod K Mishra1, Judy M Teale1,2  
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Neurocysticercosis (NCC) is one of the most common parasitic infections 
of the Central Nervous System (CNS) caused by the metacestode (larva) of 
the tapeworm Taenia solium. The majority of the associated pathogenesis is 
attributed to the immune response against the metacestode stage of the 
parasite. In the murine model of NCC, immunopathogenesis leads to 
differential breakdown of the Blood Brain Barrier (BBB) resulting in 
leakage of blood borne molecules and leukocytes that contribute to CNS 
pathology. The pial vessels of the BBB are most affected in comparison to 
the BBB associated with the vasculature of other CNS compartments, 
particularly parencyhmal vessels. In this study, we describe a 
comprehensive study to compare the genome wide gene expression of pial 
vessels in the brains of mice that were infected or mock-infected with the 
closely related parasite Mesocestoides corti that mimics the human form of 
the disease. Endothelial cells from pial vessels were labeled in-vivo by 
injecting Ricinus communis agglutinin conjugated with rhodamine dye, and 
isolated by utilizing laser capture microdissection. Differentially expressed 
genes were assessed by microarray. Overall 397 genes were found to be 
differentially regulated by infection including several angiostatic and 
angiogenic chemokines implicated in the trafficking of leukocyte subsets 
observed during NCC. Realtime RT-PCR analyses validated the pattern of 
gene expression obtained from microarray analyses. In addition, the protein 
expression profile of several chemokines, including CCL5 and CCL9, was 
examined by immunofluorescence staining and found to be upregulated in 
pial vessels from infected mice which correlated with the increased 
transcripts observed in microarray and realtime RT-PCR. Analyses for the 
biological significance of differentially expressed genes using Ingenuity 
Pathway Analysis software suggested their roles in immune response, cell 
death and development, connective tissue disorder and metabolism. Our 
data delineate infection-induced changes in the expression of genes 
associated with both immunity and disease, and collectively provide insight 
into the dysfunction of the BBB and mechanisms associated with leukocyte 
infiltration during murine NCC.  
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ENHANCEMENT OF BLOOD BRAIN BARRIER (BBB) IS THE MOST 
IMPORTANT FACTOR IN PREVENTING ANIMALS FROM 
DEVELOPING RABIES 
 
Zhen F Fu1,2, Hualei Wang1,2  
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Rabies remains a public health threat with more than 70,000 fatalities each 
year around the world. Vaccination has been proven to be the best way to 
prevent rabies. However, current vaccines are too expensive for people who 
need the most. Once symptoms occur, the disease is almost always fatal. 
There was only one reported survival in the history in patient without any 
immunological intervention. It was found that this patient had high levels of 
virus neutralizing antibodies in the CSF at the time of clinical onset. Thus it 
is hypothesized that immune effectors in the CNS might be important in 
recovery from clinical rabies. To allow immune effectors to enter the CNS, 
the enhancement of the BBB has been found to be the most important. In 
our study, we have constructed recombinant rabies viruses expressing 
chemokines/cytokines and investigated the possibility of using these 
construct to clear rabies virus from the CNS and to prevent animals from 
developing rabies. It was found that administration by direct intracerebral 
injection of these viruses can prevent mice from developing rabies as late as 
5 days after infection with wild-type rabies virus. These recombinant 
viruses can induce expression of chemokines/cytokines, enhance the BBB 
permeability, allow infiltration of inflammatory and other immune cells 
into, and clear not only the recombinant virus, but also wild-type rabies 
virus from the CNS. Thus these viruses may have potential to be developed 
as therapeutics for clinical rabies. 
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THE BLOOD-BRAIN AND THE BLOOD-CEREBROSPINAL FLUID 
BARRIERS PROVIDE DIFFERENT MOLECULAR CUES FOR T CELL 
ENTRY INTO THE CNS 
 
Britta Engelhardt  
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Central nervous system (CNS) homeostasis is a prerequisite for the proper 
communication of neuronal cells. To this end, the endothelial blood-brain 
barrier (BBB) and the epithelial blood-cerebrospinal fluid barrier (BCSFB) 
tightly seal off the CNS from the continuously changing milieu within the 
blood stream. It is now well established that in spite of the presence of these 
barriers the CNS is subject to immune surveillance and immune mediated 
pathogenic events. Numerous studies in an animal model for multiple 
sclerosis, experimental autoimmune encephalomyelitis (EAE), have 
elucidated that memory T cells can cross the non-inflamed BBB or BCSFB 
using specific molecular keys and gain access to the cerebrospinal fluid 
(CSF) drained ventricular, subarachnoidal and perivascular spaces. If these 
pioneer T cells encounter their specific antigen on antigen presenting cells 
strategically localized immediately behind the brain barriers, reactivation of 
the T cells will trigger a local inflammatory response leading to the 
stimulation of the BBB. The activated BBB will then provide novel traffic 
signals allowing for the entry of large numbers of circulating inflammatory 
cells into the perivascular spaces and finally across the glia limitans into the 
CNS parenchyma, where they progress to initiate tissue injury.  
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LOCALISED, INDUCIBLE AND SIZE-SELECTIVE MODULATION OF 
NEURONAL BARRIERS; AN AAV APPROACH 
 
Matthew Campbell, Marian Humphries, Anh Nguyen, Sophie Kiang, Paul 
Kenna, Lawrence Tam, Jane Farrar, Pete Humphries  
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Systemic access of low molecular weight drugs to the brain and retina is 
normally blocked, to a large degree, by the tight junctions of the endothelial 
cells lining the microvasculatures supplying these organs– the blood-brain 
and inner blood-retina barriers (BBB and iBRB). We describe a procedure 
for controlled, periodic, reversible modulation of selected regions of the 
BBB or the iBRB based on incorporation into an AAV2/9 vector of a 
doxycycline-inducible gene encoding shRNA targeting claudin-5, one of 30 
or so proteins constituting the tight junctions of the BBB and iBRB. The 
vector may be introduced stereotaxically into pre-selected regions of the 
brain or into the retina, rendering these regions permeable to low molecular 
weight compounds up to approximately 1kDa for the period of time during 
which the inducing agent, doxycycline, is administered in drinking water, 
but excluding potentially toxic higher molecular weight materials such as 
anaphylatoxins, soluble enzymes, pathogens etc. The process does not 
induce neuronal edema and has no significant impact on neuronal 
transcription. Using the retina as a model for functional assays, we report on 
the use of barrier modulation in tandem with systemic drug therapy to 
prevent retinal degeneration and to suppress laser-induced choroidal 
neovascularisation (CNV), the latter being the hallmark pathology 
associated with wet age-related macular degeneration (AMD). These 
observations constitute the basis of a minimally invasive approach to low 
molecular weight drug therapy of neuroretinal and neurodegenerative 
disorders while also providing a platform for the screening of compounds 
currently deemed unsuitable for neuronal indications. 
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Studies have shown that modulation of the receptor-mediated and 
endogenous cannabinoid system is neuroprotective in various settings of 
neuroinflammation. However, the selective activation of the cannabinoid 
type-2 receptor (CB2R) lacks further characterization in whether agonist of 
this type can affect cerebral vascular inflammatory response and barrier 
function. We used lipopolysaccharide (LPS from E. coli 0127:B8), released 
from gram-negative bacteria, to induce systemic endothelial activation. 
Cranial window and intravital microscopy were used to directly observe 
leukocyte-endothelial interactions in the mouse brain after LPS (6 mg/kg) 
injection. Animals were treated either with the CB2R agonist JWH-133 (10 
mg/kg) or the novel CB2R agonist, O-1966 (5 mg/kg), concurrently with 
LPS. Our results revealed that LPS exposure induced a marked increase in 
leukocyte rolling and adhesion (6-fold by 4 hours, p<0.05) on brain 
endothelium after LPS inoculation. Leukocyte rolling and adhesion were 
both significantly reduced by JWH-133 and O-1966 in the LPS-treated 
animals (2-fold, p<0.05). Analysis of BBB function was also evaluated 
using Evans blue extravasation ex-vivo and Transendothelial Electrical 
Resistance (TEER) in-vitro. Permeability of the BBB (by Evans blue) was 
increased after LPS injection (2.2- fold, p<0.05) and these changes were 
prevented by treatment with O-1966. Barrier integrity monitored by TEER 
in human brain endothelial cells showed that CB2R agonists, O-1966 or 
JWH133, increased barrier tightness and restored barrier integrity. Thus, 
our findings demonstrate that under inflammatory insult, selective CB2R 
activation greatly attenuates leukocyte-endothelium engagement and 
provides protection to the BBB. CBR2 activation could be a new strategy 
for BBB protection during neuroinflammation. 
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LIPOPROTEIN PARTICLES CROSS THE BLOOD BRAIN BARRIER IN 
DROSOPHILA 
 
Marko Brankatschk, Wilhelm Palm, Suzanne Eaton  
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Circulating lipoprotein particles are systemic lipid and protein carriers that 
may also represent a communication link between different tissues. The 
CNS however, is wrapped by the blood–brain barrier (BBB) which 
regulates the passage of nutrients and signaling molecules from the 
periphery into the brain. Whether lipoproteins cross the BBB in vivo has 
been controversial, and no clear requirement for circulating lipoproteins in 
brain development has been shown.  
We address these issues in Drosophila, which has a functionally conserved 
BBB, and lipoproteins that functionally resemble those of vertebrates. We 
show that the Drosophila lipoprotein Lipophorin (Lpp) exists in two 
isoforms. Both isoforms cross the BBB, but accumulate on distinct subsets 
of cells within the brain. Further, Lpp carries both sterol-linked and GPI-
linked proteins into the circulation and transports them across the BBB. 
Finally, Lpp promotes neuroblast proliferation by a mechanism that does 
not depend on delivery of dietary lipids.  
In addition, a second lipoprotein, LTP (lipid transfer protein), also crosses 
the BBB and accumulates on an even more restricted set of neurons by a 
mechanism that depends on the LDL receptor homologues LPR1 and LPR2. 
These results suggest that lipoproteins may represent an important vehicle 
for communication between the central nervous system and peripheral 
tissues. 
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NEISSERIA MENINGITIDES, A BACTERIAL PATHOGEN, CROSSES 
THE BLOOD BRAIN BARRIER BY HIJACKING THE B2-
ADRENOCEPTOR-B-ARRESTIN PATHWAY 
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The tropism of N. meningitidis for the meninges reveals the efficiency with 
which the interactions between this pathogen and the brain 
microvasculature modify the BBB function.  
Adhesion of the meningococcus is mediated by type IV pili that induce a 
localized remodeling of the sub cortical cytoskeleton, leading to the 
formation of endothelial membrane protrusions that anchor bacterial 
colonies at the endoluminal face of the endothelial cell membrane, allowing 
a better resistance to blood flow. N. meningitidis is also able to recruit the 
polarity complex Par3/Par6/aPKC that re-routes junctional molecules at the 
site of bacterial cell interaction thus opening a paracellular route for bacteria 
to cross the endothelial barrier. 
The signaling receptor activated by the pathogen remained unknown. We 
report that N. meningitidis specifically stimulates a β2-adrenoceptor β-
arrestin signaling pathway in human brain endothelial cells (hCMEC/D3), 
which ultimately traps β-arrestin interacting partners, such as cytoskeletal 
and junctional proteins under bacterial colonies. These molecules are 
progressively depleted from endothelial cell junctions resulting in 
anatomical gaps likely used by bacteria to penetrate into tissues.  
Pharmacological activation of β2-adrenoceptors with specific agonists that 
induce their endocytosis prevents signaling events downstream of N. 
meningitidis adhesion and inhibits bacterial crossing of endothelial cell 
monolayers. These results reveal a novel strategy used by a pathogen to 
hijack host cell signaling machineries and open the blood brain barrier. 
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DIAGNOSTIC ULTRASOUND AND SONOVUE OPEN THE BLOOD-
BRAIN BARRIER AND ITS EFFECT ON COGNITIVE FUNCTION. 
 
Lei Zhang1, Qiang Wang1, Xiaodong Zhou1, Haili Su2, Zan Zhang2, Shiquan 
Wang1, Lize Xiong1 
 
1Xijing Hospital of the Forth, Department of Anesthesiology , Xi'an, 
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Purpose: The objective of this work was to investigate the recovery time of 
the change of the blood-brain barrier’s permeability by diagnostic 
ultrasound and contrast agent in rat, and determine whether the opening 
could affect the cognitive ability.  
 
Materials and Methods: All animals were anesthesed by phenobarbital, the 
hair of the right eye to ipsilateral ear to the top of skull was removed before 
treatment. The SonoVue was administrated intravenously at the dosage of 7 
ml/ kg, and the ultrasound was delivered to rat brain at 1. 3 mechanical 
indexes (MI) for 10 minutes, then the permeability of the BBB was 
investigated at different times after the contrast imaging by evans blue dye 
exudation . Morris water maze was used for assessing the spatial learning 
and memory 24 hours after the treatment. Arterial blood gas samples were 
obtained at three time points: before the SonoVue injection, right at 5mins 
of the ultrasound exposure, after the treatment. The cerebral blood flow was 
measured before ultrasound exposure with SonoVue and after the treatment.  
 
Result: Evens blue could be detected in the local brain after the contrast 
imaging and the permeability’ change recovered in 6 hours (P<0.05). The 
escape latency and pathlength to the platform decreased compared to the 
control groups (P<0.05). Ph, PaO2, PaCO2 were no different among the 
three time points (P>0.05).Cerebral blood flow increased after contrast 
imaging (P<0.05).  
 
Conclusion: Blood-brain barrier could open after diagnostic ultrasound and 
contrast agent in rat. The cognitive function was improved after ultrasound 
with SonoVue. Arterial blood gas is not affected. Cerebral infusion 
improves after the treatment.  
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The maintenance of organism-wide metabolic and chemical homeostasis is 
a biological process central to life that is impossible to fully reconstitute in 
vitro. In metazoans, small molecule utilization is regulated by networks that 
operate at cellular, tissue and organism-wide levels to modulate both 
physiology and behavior. A major challenge is to understand how 
organisms integrate these diverse pathways to control small molecule 
localization. All eukaryotes manifest chemical partition physiology to 
protect and maintain susceptible organ systems like the CNS, promote the 
best of use of energy stores, and to deliver the building blocks of biology. 
The nematode C. elegans is a useful model system to understand how small 
molecule partition is regulated in multicellular organisms. Many of the 
known mammalian pathways that regulate feeding, nutrient uptake, 
transport, energy storage and utilization in mammals are conserved in C. 
elegans. Notably, the robust genetic tools available in C. elegans have 
facilitated the identification of pathways as well as the targets of 
compounds that induce phenotypes in this organism. Pharmacological tools 
can complement the many genetic tools that exist in C. elegans in that they 
allow better temporal control, their dose-response variation gives an effect a 
continuous allelic series, they can deal effectively with functional 
redundancy, and their ease of implementation facilitates genetic interaction 
studies. Furthermore, pharmacological tools are easily portable between 
systems to discover special application to highly integrated and protected 
barriers like the blood brain interface (BBI).To systematically discover 
compounds that modulate small molecule localization in C. elegans, we 
developed a microscopy-based screen that utilizes the vital dye Nile Red to 
visualize chemical compartments in the worm. These small molecules are 
vetted by several genetic and ex vivo systems and tested at the fly BBI for 
special modulation function at the humoral/CNS interface of Drosophila.  
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VISITOR INFORMATION 
 
EMERGENCY                CSHL                          BANBURY 
Fire (9) 742-3300 (9) 692-4747 
Ambulance (9) 742-3300 (9) 692-4747 
Poison (9) 542-2323 (9) 542-2323 
Police (9) 911 (9) 549-8800 
Safety-Security Extension 8870  
 
Emergency Room 
Huntington Hospital 
270 Park Avenue, Huntington 
631-351-2300 
(1037)  
Dentists 
Dr. William Berg 
Dr. Robert Zeman 
 
631-271-2310 
631-271-8090 
Doctor 
MediCenter 
234 W. Jericho Tpke., Huntington Station 
631-423-5400 
(1034) 
Drugs - 24 hours, 7 days 
Rite-Aid 
391 W. Main Street, Huntington 
631-549-9400 
(1039) 
Free Speed Dial 
Dial the four numbers (****) from any tan house phone to place a 
free call. 
GENERAL INFORMATION 
 
Books, Gifts, Snacks, Clothing, Newspapers 
 BOOKSTORE   367-8837 (hours posted on door) 
 Located in Grace Auditorium, lower level. 
 
Photocopiers, Journals, Periodicals, Books, Newspapers 
 Photocopying – Main Library 
 Hours:  8:00 a.m. – 9:00 p.m. Mon-Fri 
             10:00 a.m. – 6:00 p.m. Saturday 
Helpful tips - Obtain PIN from Meetings & Courses Office  
to enter Library after hours.  See Library staff for photocopier 
code. 
 
Computers, E-mail, Internet access 
 Grace Auditorium 
 Upper level: E-mail only 
 Lower level: Word processing and printing. 
 STMP server address: mail.optonline.net 
 To access your E-mail, you must know the name of your  
 home server.    
 
Dining, Bar 
 Blackford Hall 
  Breakfast  7:30–9:00, Lunch 11:30–1:30, Dinner  5:30–7:00 
  Bar  5:00 p.m. until late  
 Helpful tip - If there is a line at the upper dining area, try the  
 lower dining room 
 
 
 
Messages, Mail, Faxes 
 Message Board, Grace, lower level 
 
Swimming, Tennis, Jogging, Hiking 
June–Sept. Lifeguard on duty at the beach. 12:00 noon–6:00 p.m.  
Two tennis courts open daily. 
 
Russell Fitness Center 
 Dolan Hall, east wing, lower level 
 PIN#:  Press 64580 (then enter #) 
 
Concierge 
 On duty daily at Meetings & Courses Office. 
After hours – From tan house phones, dial x8870 for 
assistance 
  
Pay Phones, House Phones 
Grace, lower level; Cabin Complex; Blackford Hall; Dolan Hall, 
foyer  
 
CSHL’s Green Campus 
 
Cold Spring Harbor Laboratory is pledged to operate in an 
environmentally responsible fashion wherever possible.  In the past, 
we have removed underground oil tanks, remediated asbestos in 
historic buildings, and taken substantial measures to ensure the 
pristine quality of the waters of the harbor. Water used for irrigation 
comes from natural springs and wells on the property itself.  Lawns, 
trees, and planting beds are managed organically whenever possible.  
And trees are planted to replace those felled for construction 
projects.   
 
Two areas in which the Laboratory has focused recent efforts have 
been those of waste management and energy conservation.  The 
Laboratory currently recycles most waste.  Scrap metal, electronics, 
construction debris, batteries, fluorescent light bulbs, toner cartridges, 
and waste oil are all recycled.  For general waste, the Laboratory uses 
a “single stream waste management” system, removing recyclable 
materials and sending the remaining combustible trash to a 
cogeneration plant where it is burned to provide electricity, an 
approach considered among the most energy efficient, while providing 
a high yield of recyclable materials. 
 
Equal attention has been paid to energy conservation.  Most lighting 
fixtures have been replaced with high efficiency fluorescent fixtures, 
and thousands of incandescent bulbs throughout campus have been 
replaced with compact fluorescents.  The Laboratory has also 
embarked on a project that will replace all building management 
systems on campus, reducing heating and cooling costs by as much 
as twenty-five per cent. 
 
Cold Spring Harbor Laboratory continues to explore new ways in 
which we can reduce our environmental footprint, including 
encouraging our visitors and employees to use reusable containers, 
conserve energy, and suggest areas in which the Laboratory’s efforts 
can be improved. This book, for example, is printed on recycled 
paper. 
                       1-800 Access Numbers 
 
 AT&T  9-1-800-321-0288 
 MCI  9-1-800-674-7000 
 
Local Interest 
 Fish Hatchery   631-692-6768 
 Sagamore Hill   516-922-4447 
 Whaling Museum   631-367-3418 
 Heckscher Museum  631-351-3250 
 CSHL DNA Learning  x 5170 
   Center 
 
New York City 
 Helpful tip - 
 Take Syosset Taxi to Syosset Train Station 
 ($8.00 per person, 15 minute ride), then catch Long Island  
 Railroad to Penn Station (33rd Street & 7th Avenue).   
 Train ride about one hour. 
 
   TRANSPORTATION 
Limo, Taxi 
 Syosset Limousine  516-364-9681  (1031) 
 Super Shuttle  800-957-4533  (1033) 
  To head west of CSHL - Syosset train station 
  Syosset Taxi  516-921-2141  (1030) 
 To head east of CSHL - Huntington Village  
  Orange & White Taxi 631-271-3600  (1032) 
Executive Limo  631-696-8000  (1047) 
 
Trains 
 Long Island Rail Road   822-LIRR  
 Schedules available from the Meetings & Courses Office. 
 Amtrak   800-872-7245 
 MetroNorth   800-638-7646 
 New Jersey Transit  201-762-5100 
 
Ferries 
 Bridgeport / Port Jefferson 631-473-0286 (1036) 
 Orient Point/ New London 631-323-2525 (1038) 
 
Car Rentals 
 Avis   631-271-9300 
 Enterprise   631-424-8300 
 Hertz   631-427-6106 
  
Airlines 
 American   800-433-7300 
 America West  800-237-9292 
 British Airways  800-247-9297 
 Continental   800-525-0280 
 Delta   800-221-1212 
 Japan Airlines  800-525-3663 
 Jet Blue   800-538-2583 
 KLM   800-374-7747 
 Lufthansa   800-645-3880 
 Northwest   800-225-2525 
 United   800-241-6522 
 US Airways   800-428-4322 
